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Abstract
The ubiquitin signaling pathway (USP) consists of hundreds of enzymes which are tightly
regulated for proper maintenance of intracellular protein level homeostasis. The main goals of
this thesis were to characterize the interaction of two proteins involved in the USP, the E3
ubiquitin ligase called parkin, and the Deubiquitinating (DUB) enzyme, ataxin-3. The effect of
disease-state substitutions in the parkin ubiquitin-like domain (UbLD) on the interaction with
ataxin-3 was investigated through NMR 1H-15N HSQC titration experiments and affinity binding
assays. The three UIM regions in ataxin-3 bind the hydrophobic patch of parkin UbLD (KD = 230
µM) and are proposed to use a multivalent binding mechanism. The disease-state UbLD proteins
(UbLDV15M, UbLDR33Q, UbLDK48A) retain their interaction with ataxin-3. Other DUB enzymes
and E3 ligases have been reported to have regulatory interplay, which has triggered interest in
studying protein pairings such as ataxin-3 and parkin.
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Chapter 1
INTRODUCTION
1.1

The ubiquitin signaling pathway
Protein degradation is a tightly orchestrated process that is required to maintain

protein level homeostasis, which is essential for biological pathways such as cellular
division, DNA repair, and proteasomal degradation. The ubiquitination signaling pathway
(USP) is most famously known for its role in eukaryotic protein degradation by sending
specific proteins to the proteasomal degradation machinery at the right time. The
ubiquitin (Ub) molecule is 8.6 kDa, globular in shape, very robust and highly conserved
in all eukaryotes. A cascade of three enzymes, the ubiquitin-activating (E1), ubiquitinconjugating (E2), and ubiquitin-ligase (E3) enzymes are utilized for attaching a monoubiquitin species or building a chain of ubiquitin moieties on a substrate (Figure 1.1).
These enzymes were originally named in the order that they were eluted from an anionexchange column (1). The covalent attachment of Ub moieties to substrates is an ATP
driven process and is done so in a specific manner which is facilitated by the multiple
combinations of E1, E2 and E3. Of the three classes of proteins involved in
ubiquitination, the E3 ubiquitin ligase proteins has been an especially attractive target for
macromolecular research due to the discovery of more than 1000 different homologues,
suggesting that the E3 protein is heavily contributing to the substrate specificity in the
pathway (2). To date there are ~1000 human E3 enzymes identified, ~40 E2 enzymes,
and 2 E1 enzymes identified (3). An addition to the complexity of Ub attachment is the
type of linkage that can be made between adjacent Ub moieties in a poly-Ub chain. There
are 7 linkage possibilities, due to the presence of seven lysine residues within the Ub
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Figure 1.1 Schematic of the conjugation and recycling process in the ubiquitin signaling

Figure 1.1 Schematic of the ubiquitin conjugation and recycling process in the
ubiquitin signaling pathway. Ubiquitin (Ub) is a signaling molecule that is
conjugated onto a target protein to signal for essential cellular processes such as a
degradation signal, DNA repair, or endocytosis. The Ub is activated by the E1
activating enzyme, which requires an ATP molecule for the formation of a high
energy thiolester bond to form between E1-Ub. The E1 then transfers the Ub
moiety to the E2 enzyme, forming the Ub-E2 complex. Then the E3 acts as a
scaffold protein to direct the Ub directly from the E2 to the target substrate, on the
condition that it is a RING-type E3 enzyme. The target protein can have either a
monoubiquitin attached or, after successive rounds of the E1-E2-E3 cascade, the
target protein can have a poly-Ub chain attached. This process is reversible by
deubiquitinating (DUB) enzymes, which act to detach Ub moieties to recycle Ub
molecules, edit Ub conjugation errors, or for Ub processing.

3

molecule, and the arrangement of the linkages provide variety in the orientation of the Ub
chain in three dimensional space. The type of linkage that is created in a poly-Ub chain,
is a unique signal, which determines the fate of the substrate that its attached to. The most
studied linkage pattern is the Lys48 Ub linkage which is known to signal for proteasomal
degradation (4).
The multistep enzymatic reaction for attachment of a ubiquitin moiety to a
substrate protein is also a reversible process. The group of enzymes that perform the
reverse reaction are known as ubiquitin specific proteases or deubiquitinating (DUB)
enzymes and in mammals there are 5 gene families of DUB enzymes: Ubiquitin Cterminal Hydrolases (UCHs), Ubiquitin-specific Peptidases (UBPs), Ovarian Tumor
domain proteins (OTU), Josephin proteins and the Jab1/MPN domain-associated
Metalloisopeptidase (JAMM) domain proteins (5). Most of these DUB enzymes are
cysteine proteases, which utilize three residues, called the catalytic triad, including the
cysteine that has the essential thiol group for catalyzing the Ub hydrolysis (6) (Figure
1.2).
Currently, there is interest in understanding how E3 enzymes are able to recognize
specific substrates, and due to the large numbers of E2 and E3 enzymes available, many
E2/E3 combinations are possible. Interestingly, certain E3 ligases have been found to
interact with specific DUB enzymes, which seems counter-intuitive in the context of
energetics used for Ub chain building. However, when considering the possibility of
errors in attaching Ub to the correct substrate and using the correct linkage, and constant

4

Figure 1.2 Ribbon representation of DUB enzymes, each enzyme belongs to one
of the five families of DUB enzymes. The DUB enzyme belonging to the USP, UCH,
OTU, and MJD domains all have a conserved catalytic triad consisting of a Cys, His
and Asp residue. The catalytic triad is depicted in blue with the side chains portrayed.
The JAMM domain is a metalloisopeptidase and does not utilize a catalytic triad. The
name of the protein is indicated beside the catalytic domain ribbon representation. The
ribbon depictions were created in PyMOL and the PDB for USP7 (1NBF), UCH-L3
(1XD3), OTU2 (1TFF), ataxin-3 (1YXB), and JAMM (1R5X).
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reversibility requirements for cellular environment changes, there seems to be a need for
DUB enzymes to rapidly edit these problems to adapt to a constantly changing cellular
environment (7, 8). When the maintenance of protein homeostasis is abnormal in the cell,
disease prone events like protein misfolding and aggregation can occur. Enzymes
involved in the USP have been linked to neurodegenerative diseases, such as Parkinson’s
disease and Spinocerebellar ataxias (7).

1.2

E3 ubiquitin ligase
E3 Ub-ligases fall under two major groups, the HECT (Homologous to E6-AP C-

terminal domain) or RING (Really Interesting New Gene) group (8). Apart from their
unique structural features, they are also set apart from one another in their function as an
E3 ligase protein. The HECT type E3 ligases form a thioester intermediate with Ub and
further mediates the transfer to the substrate protein. RING type E3 enzymes are different
and often described as more of a scaffold protein, which functions to interact with an E2Ub conjugate and substrate to mediate the transfer of the Ub moiety directly from the E2
(8).
1.3

Parkin

1.3.1

PARK2 gene and domain architecture, expression of parkin, subcellular

localization and function
PARK2 is the gene encoding the parkin protein and its location in the human
genome, based on positional cloning, is on the long arm of chromosome 6 (6q25.2-27)
(9). PARK2 is a large gene spanning 1.5 megabases containing 12 exons and is expressed

6

in many tissue types such as brain, skeletal muscle, and heart (10, 11). Interestingly, it is
expressed in many areas of the brain including the substantia nigra (10).
Parkin is a RING-type E3 ligase composed of 465 residues and has a molecular
weight of 52 kDa. Parkin consists of multiple domains; listed from the N-terminus to Cterminus, UbLD (Ubiquitin-Like Domain), UPD (Unique-Parkin Domain), RING0,
RING1, IBR (In-Between-RING), followed by RING2 (12) (Figure 1.3). The RING
domains and IBR domain contain two Zn2+ ions each that are coordinated by cysteine and
histidine residues. Without the Zn2+ ions, two of the protein domains (IBR, RING2)
become completely unfolded (12).
The discoveries that identified parkin as a USP protein came from evidence that it
has E3 ligase activity and could interact with E2 enzymes, such as UbcH7 and UbcH8
(13). Originally, E3 ligases were thought to be constitutively active, however, after
further investigation, parkin activity was proposed to be governed by autoregulation,
post-translational modification, such as ubiquitination or/and phosphorylation (14). Many
putative substrates have been identified for parkin such as synphillin-1 (15), Pael-R (16),
cyclin E (17) and several others. A popular hypothesis for parkin function is that it is
fundamentally important for regulating appropriate levels of its protein substrates,
especially avoiding accumulations of aggregate-prone substrates such as alpha-synuclein,
Aβ peptide and Huntington protein (13). These aggregate-prone substrates of parkin, such
as synphillin-1 and alpha-synuclein, with Ub and parkin itself have all been identified
immunopositive in nigral cell Lewy bodies (15). Recent studies show a role for parkin in
mitochondrial regulation, and its importance in retaining the mitochondrial DNA
integrity by

7

Figure 1.3 Domain topology of the E3 ligase parkin protein. Parkin is a 465 residue
protein and is composed of six domains. It has an N-terminal Ubiquitin-like domain
(UbLD), which was structurally solved by NMR. Following the UbLD, is the unique
parkin domain (UPD). RING0 and RING1 (really interesting new gene) are next in the
sequence, followed by an In-Between RING (IBR) domain, which was also
structurally solved by NMR spectroscopy. The most C-terminal domain is the RING2
domain. Unlike the IBR and RING domains, the UbLD and the UPD domains do not
coordinate two zinc ions. The ribbon diagrams of the UbLD and IBR were made using
PyMOL and the PDB for parkin UbLD is 1IYF, and for parkin IBR is 2JMO.
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promoting repair and by protection from reactive oxidative stress (18). Parkin has also
been reported to bind tightly with microtubules for stabilization and quality control
purposes, and interestingly, the microtubule network is crucial for another type of protein
degradation mechanism known as aggregsomal degradation (19). The multiple roles of
parkin in different cellular processes are still being investigated and this is an important
aspect to appreciate especially when considering the outcome of pathogenic mutations on
parkin.

1.3.2

N-terminal ubiquitin like domain of the parkin protein
UbLD proteins are often found within multidomain proteins and the function of

each UbLD within the USP is still under investigation (20). Like Ub, they possess the βgrasp fold which has a hydrophobic face on the solvent exposed side of the β-sheets
(Figure 1.4). What is unique to UbLD proteins, compared to the Ub molecule, is that they
are unable to be conjugated to the lysine residue of a substrate protein because they lack
the C-terminal glycine. Not to be confused with Ub-like domains, SUMO, ISG15,
NEDD8 are examples of free Ub-like proteins that are covalently attached to substrates
utilizing the same mechanism of Ub conjugation. The parkin N-terminal UbLD has 30%
identity and 62% homology with the human Ub molecule (21) (Figure 1.4). The function
of the UbLD is thought to be a recruitment domain for substrate recognition. It has been
previously shown to interact with o-glycosylated alpha-synclein, an aggregation prone
protein found in Lewy bodies; S5a, a proteasomal subunit; Eps15 an endocytosis
involved protein; and ataxin-3, a DUB enzyme (2, 22, 23).

9

Figure 1.4 Structural and sequence comparison between the human Ub and
parkin UbLD molecule. A) Both the parkin UbLD (left) and Ub (right) molecule
share the beta-grasp fold which consists of 5 β-sheets and 2 α-helices. B) The parkin
UbLD and human Ub sequence share 30% sequence identity, which is indicated with
a red background. The ribbon diagram was created in PyMOL and the PDB for the
parkin UbLD is 1IYF and human Ub is 1UBQ.
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1.3.3

Autosomal recessive juvenile Parkinsonism is linked to the PARK2 gene
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease

next to Alzheimer’s disease. The usual age of onset for PD is past the age of 50, however,
there are approximately 5-10% of PD patients that have the misfortune of being
diagnosed at a very early age. Acquiring the disease before the age of 40 is uncommon
compared to the idiopathic late-onset form of the disease and is labeled as early-onset PD
(10). Within this group of early-onset PD patients, a small group will have inherited it in
an autosomal recessive fashion with complete penetrance. Autosomal Recessive Juvenile
Parkinsonism (ARJP) affects men and women equally and its prevalence across various
regions seems to be similar. The pathogenic characteristic of many idiopathically
contracted patients include cytoplasmic insoluble protein aggregate, known as Lewy
bodies (13). However, Lewy bodies are infrequently presented in parkin linked ARJP
patients (24, 25).
ARJP exhibits locus heterogeneity; there are five known monogenic mutants that
are linked to the same disease phenotype and same inheritance pattern. The most
common form of ARJP arises from PARK2 gene mutations, which codes for the parkin
protein, and accounts for 50% of early-onset PD (26). Initial ARJP disease cases were
characterized in Japanese families and were mostly caused by large exon deletions, but as
the search for parkin-linked ARJP patients progressed, more single amino acid
substitutions were characterized as disease mutations (21). These mutations were found
throughout the PARK2 gene with a concentration of missense type mutations occurring
in the RING1-IBR-RING2 C-terminus region (14, 27) (Figure 1.5).

Figure 1.5 Schematic representation of parkin and the ARJP substitutions identified within the parkin sequence.
The sites of the disease state mutations that cause an early-onset Parkinson’s disease, by an autosomal recessive inheritance
pattern, are indicated below the domain representation of parkin. ARJP single amino acid substitutions are found
throughout the parkin protein with the majority of them identified in the RING1-IBR-RING2 regions. Not all of the
substitutions are shown in this figure. The residue numbers that are indicated above the domain schematic represent the
boundaries of each domain within the parkin protein.
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1.4

Ataxin-3

1.4.1

ATXN3 gene topology
The gene that encodes for the ataxin-3 protein is called ATXN3 and is located on

chromosome 14 (14q24.3-q32) (28). The human ATXN3 gene is approximately 48 Kb
and is composed of 11 exons (29). There is a CAG trinucleotide repeat located within
exon 10 that is prone to unstable expansions which cause neurodegeneration when the
repeat number passes a threshold of >45 (29). Meanwhile, wild-type alleles can range
from 11 to 44 CAG trinucleotide repeats (30).

1.4.2

Ataxin-3 domain architecture
The ataxin-3 protein has often been described as having unique domain topology

due to the arrangement and number of Ubiquitin Interacting Motif (UIM) regions it
possesses. Ataxin-3 is composed of an N-terminal catalytic Josephin domain, spanning
residues 1-170 (Figure 1.6). The Josephin domain contains the catalytic cysteine (Cys14)
that is required for its DUB activity. Following the folded Josephin domain are two
tandem UIM regions, (UIM1, UIM2). UIM1 spans residues 224-243 and UIM2 spans
residues 244-263. Following UIM2, there is a variable glutamine tract that can vary from
11 to 44 repeats, which are non-disease causing lengths (30). At the C-terminus of ataxin3, following the poly-glutamine tract, there is a third UIM that spans residues 331-348,
(UIM3) (Figure 1.6).
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Figure 1.6 Schematic of the domain topology within the ataxin-3 DUB enzyme.
Ataxin-3 consists of 5 distinct regions: the N-terminal catalytic Josephin domain
(residues 1-170); two UIM regions (residues 224-243 and 244-263); a variable polyglutamine expansion that can consist of 11-44 residues for a non-disease state; and a
C-terminal UIM region (residues 331-348). The N-terminal Josephin domain was
structurally determined by both NMR spectroscopy and X-ray crystallography. The
ribbon diagram was made using PyMOL and the PDB for ataxin-3 Josephin domain is
1YZB.
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1.4.3

Ataxin-3 expression, splice isoforms, subcellular localization and function
The normal non-expanded form of human ataxin-3 is approximately 42 kDa,

depending on the glutamine tract variability, and is expressed ubiquitously in many
tissues including neuronal tissue. Ataxin-3 is predominantly a cytoplasmic protein based
on immunohistochemical studies in various human neuronal cells (31). The mechanisms
to regulate the expression of the ATXN3 gene are unclear, due to the variation at the 3’
untranslated region (UTR) and the lack of study in the 5’ UTR (29).
Ataxin-3 functions as a deubiquitinating (DUB) enzyme, and falls under the
Josephin gene family of DUB proteases because of its sequence homology with other
Josephin genes (6). It has a preference to detach Lys63 linked poly-Ub chains, in vitro
(32-34). The ataxin-3 protein participates in the ubiquitin-signalling pathway based on
three pieces of evidence; (a) it is composed of a catalytic Josephin domain which has a
DUB function, (b) it has three UIM sites involved in poly-Ub and UbLD interactions, and
(c) it has many binding partners involved in the proteasomal pathway such as VCP
(valosin-containing protein) (35), E6,AP (Ubiquitin ligase E3A) (36), and parkin (37).
However, ataxin-3 is not restricted in participating with just the USP, it has also been
found to play a role in DNA repair and ERAD (endoplasmic reticulum associated
degradation) (38, 39).
Ataxin-3 has been shown to have over 50 splice variants but only two have been
extensively characterized and found to be expressed in a tissue specific manner. One of
the splice variants encodes the full-length sequence which includes all three UIM sites.
The other splice variant lacks the C-terminal third UIM site but includes the
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polyglutamine stretch of ataxin-3 (40, 41). In human and murine brain, the splice
variant encoding three UIM sites is the predominant isoform (40).

1.4.4

Ubiquitin interaction motif
Poly-Ub binding assays involving the human proteasomal subunit, S5a, were used

to identify the UIM, though at the time it was originally known as the pUB motif (42).
The UIM is one of fifteen identified protein groups dedicated to Ub or/and UbLD
recognition. Interestingly, the Ub-recruitment domains vary in size and their threedimensional fold suggesting that Ub can accommodate an interaction for many domains,
such as the UBA (Ubiquitin-Associated), DUIM (Double-sided Ubiquitin Interacting
Motif), and CUE (Coupling of Ubiquitin conjugation to Endoplasmic reticulum
degradation) (43). All of the Ub recruitment domains have weak binding affinities to
mono Ub, in the 100 µM to 2 mM range, determined by either NMR, ITC (Isothermal
Titration Calorimetry) or SPR (Surface Plasmon Resonance) methods (43).
One of the first reviews that provided analysis of the identified UIM containing
proteins reported that the UIM is composed of twenty residues and contain a conserved
acidic stretch of approximately four residues prior to a series of highly conserved alanine
and serine residues (44) (Figure 1.7). The same group also noticed that many proteins
containing the UIM regions often have more than one UIM site and can present itself in a
wide variety of proteins with roles in endocytosis, proteasomal substrate recruitment, and
DUB function (44). Further investigation of the UIM sequences sparked notice of an
interesting trend of alternating large-small-large-small-large residues in between the two
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Figure 1.7 Sequence alignment of the ubiquitin interacting motif of human
proteins. Selected human proteins (ataxin-3, Eps15, Epsin1 S5a, Rap80) containing
ubiquitin-interacting motifs (UIM) have their UIM sequences aligned. The protein
name, UIM position, residue position, and the number of residues within the
identified UIM is indicated on the left of the sequence. The motif consists of
approximately 20 residues, starting with an N-terminal acidic stretch (red) of 3 to 5
residues followed by a hydrophobic stretch (pink). There is a conserved alanine and
serine residue that borders the hydrophobic stretch within each UIM. This sequence
alignment was created in JalView.
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acidic patches of the UIM sequences (45) (Figure 1.7). Although the UIM sites of
most proteins have high sequence similarities between one another, it cannot be assumed
that all UIM sites will interact to Ub or UbLD proteins (2).
The UIM region containing UIM1 and UIM2 of ataxin-3, spanning residues 194261, has been reported to possess α-helical structures separated by a flexible linker by
NMR studies (46). The structure of the two UIM site in Vps27, a yeast protein involved
in vacuolar protein sorting, was also characterized to have a helical conformation by Xray crystallography, NMR spectroscopy and circular dichroism (45, 47, 48). These are
just two examples of structurally determined UIM domains that are helical. Although
structures of other UIM domains have yet to be determined they are also thought to be αhelical in structure (43). It has been reported that the helical-type of Ub binding domain,
such as the UIM, DUIM and CUE are all thought to bind to the same site on Ub on its
Ile44 hydrophobic patch (43).

1.4.5

Polyglutamine expansion in ataxin-3 causes Machado Joseph Disease
Polyglutamine diseases are characterized by protein misfolding leading to

intracellular or intranuclear aggregate formation, caused by long repeats of CAG
trinucleotides encoding for a poly-glutamine expansion, which eventually lead to
neurodegeneration. The ataxin-3 protein is one of ten identified polyglutamine diseases
which causes Machado Joseph Disease (MJD) (49) when its polyglutamine stretch is
expressed passed a threshold of >45 residues. MJD is the most common dominantly
inherited ataxia. Its name ‘Machado-Joseph’ originates from observations of two Azorian
families that presented the disease in the 1970s (50). Interestingly, MJD patients exhibit a
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wide variation of clinical presentations of parkinsonism characteristics, progressive
external ophthalmoplegia, difficulty talking and difficulty swallowing (49). The affected
brain areas based on MRI and neuroimaging studies indicates that the pons, midbrain,
fourth ventricle, and basal ganglia are all affected in addition to the cerebellum and
brainstem (51-55). The polyglutamine tract lies between the second and third UIM site of
the ataxin-3 protein. The study of polyglutamine disease causing proteins are often
focused on understanding the protein conformation of the wildtype and disease state
proteins to understand how it relates to protein misfolding and aggregation. The difficulty
in performing biophysical and biochemical analyses comes from issues in purifying great
yields of the disease state proteins that are soluble in solution (56).

1.5

Scope of Thesis
Parkin and ataxin-3 are both multidomain proteins that play a role in the USP.

The aim of this work was to characterize the interaction between the recruitment domains
of these proteins. Investigation of their interaction will improve the overall understanding
of the biological roles these proteins contribute to the USP. There has been evidence to
support the direct interaction between ataxin-3 and parkin through affinity binding
assays, however, a detailed analysis of the residues that are involved, the mechanism and
the affinity of the interaction have not been deduced (23).
The goals of this thesis were:
1) Determine the binding surface on parkin UbLD when ataxin-3 is bound to it.
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2) Determine which combination of UIM region(s) in ataxin-3 are crucial for the
interaction with the parkin UbLD.
3) Propose a biologically relevant binding model for parkin and ataxin-3.
4) Address the biological consequence of structurally benign ARJP substitutions and
the interactions of these proteins with ataxin-3.
To address the goals, 1H-15N HSQC titrations and chemical shift perturbation
analyses were carried out using NMR spectroscopy to reveal residues that participate in
the binding interface, identify which UIM sequences participate in the interaction with
the UbLD and determine the binding affinity of these interactions. Analysis of the
binding affinities between the UbLD and various ataxin-3 UIM constructs, with either Cterminal UIM deletions or ‘functional knockouts’ of the UIM sites, assisted in proposing
a type of binding mechanism that could explain the parkin ataxin-3 interaction. The same
1

H-15N HSQC titration experiments were utilized for the interaction study between ARJP

substituted UbLD proteins and ataxin-3194-361, to determine how their structures are
affected by the substitution, and determine whether the ARJP substitution perturbed the
affinity of the interaction. A four-part hypothesis was proposed; a) the parkin UbLD has a
unique ataxin-3 binding site, b) all three UIMs in ataxin-3 are important for parkin
binding, c) parkin uses a multivalent binding mechanism to recruit ataxin-3, d)
structurally benign ARJP mutations in the parkin UbLD will decrease the binding affinity
to ataxin-3.
There is growing evidence to support that ataxin-3 and parkin interact with each other
to regulate both of their catalytic function (23, 37). This body of work highlights the
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interaction mechanism, binding sites, and ARJP substitutions in the interaction studies
between parkin and ataxin-3.
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Chapter 2
CHARACTERIZATION OF THE INTERACTION BETWEEN THE PARKIN
UBLD AND THE UIM REGION OF ATAXIN-3
2.1

Introduction
Parkin and ataxin-3 are both multi-domain proteins that function in the ubiquitin

signaling pathway (USP). The roles of the proteins are opposing. Parkin is an E3
ubiquitin ligase that is responsible in attaching ubiquitin (Ub) on a specific set of
substrates, whereas, ataxin-3 is a deubiquitinating (DUB) enzyme which acts to remove
Ub moieties from poly-ubiquitin chains (1). There is growing interest in the USP as
protein misfolding diseases are linked to these pathways. The concern is that when
disease mutations or malfunctions in the regulators of the USP ensue, the protein
homeostasis in the cell becomes disrupted to seed cellular aggregation and cell death.
Recently, it has been shown that the direct interaction of these two proteins can regulate
their catalytic function and turnover via autophagy (1). Interaction studies between parkin
and ataxin-3 have been previously investigated by GST binding assays and coimmunoprecipitations, however, the binding interface and mechanism for the interaction
remains unknown (1). Some difficulties in interpreting this interaction result from
purification problems of the unstable full-length parkin, and the lack of solved structures
of the full-length parkin and ataxin-3 proteins, which limits the prediction of docking
sites of the interaction. The strategy employed to overcome this obstacle was to identify
the specific region(s) of interaction and purify only these critical domains required for the
interaction. By isolating the regions of recruitment from parkin and ataxin-3, the 1H-15N
HSQC spectra will be easier to analyze and resonances can be unambiguously followed
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in an NMR titration, which was the main source of data collection. Based on
deubiquitination assays with a C-terminal deletion of the three Ubiquitin Interacting
Motifs (UIM) within ataxin-3 (Δ194-361), the C-terminus of ataxin-3 was found not to be
important for its DUB activity. It was then postulated the UIM region functions as a
recruitment domain for ubiquitin chains on substrate proteins and may be important for
positioning the ubiquitin chain for cleavage by the DUB catalytic portion of ataxin-3. The
parkin UbLD has 30% sequence identity with ubiquitin and possesses a similar 3D
structure, which made it a potential candidate for interactions with the UIM region of
ataxin-3 (3). The UIM regions of Eps15, an endocytic protein, and S5a, a regulatory 19s
subunit, have been shown to bind to the hydrophobic patch of the UbLD by NMR
chemical shift perturbation studies. However, a docking site has not been determined for
the ataxin-3 UIM region (2). Unlike the Eps15 and S5a protein, which only have two
UIMs, the ataxin-3 gene encodes a unique arrangement of three UIM regions spanning
ataxin-3 residues 224-243, 244-263, 331-348 for UIM1, UIM2, and UIM3, respectively.
Currently, there is controversial evidence whether all three UIMs are important (3, 4, 5)
for the proper functioning of ataxin-3.
In this work, the aims were to identify the binding site on the parkin UbLD for the
UIM region of ataxin-3194-361, to calculate the binding affinities, to determine which UIM
from the C-terminus of ataxin-3 interacts with parkin, and use this data to predict what
type of binding mechanism is employed for their interaction. The characterization of the
binding interaction between ataxin-3 and parkin will be utilized for predicting how
Autosomal Recessive Juvenile Parkinsonism (ARJP) substitutions might influence
binding.
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2.2

Materials and Methods

2.2.1

Parkin ubiquitin-like domain
The DNA encoding human parkin ubiquitin-like domain (1-77) was previously

inserted into the NdeI and BamHI sites of the pET44a vector (Novagen) (2). The parkin
UbLD constructs were verified by DNA sequencing (Robarts Sequencing Facility).

2.2.2

Ataxin-3 ubiquitin interacting motifs
The cDNA encoding full-length human ataxin-3 construct was a generous gift

from Dr. Edward Fon (McGill, Montreal, Quebec). The ataxin-3 cDNA contained a 14
residue polyglutamine tract as well as an N-terminal hexa-histidine tag. Site-directed
mutagenesis was previously used to incorporate a TEV cleavage site to allow for removal
of a 6-residue N-terminal histidine tag from ataxin-3 constructs. The His-tagged ataxin3194-361 construct, containing all three UIM regions, was inserted into the BamHI and
XhoI sites of the pET21a vector (Novagen). Site-directed mutagenesis was also used to
generate a C-terminal deletion construct, consisting of residues 194-261, by encoding a
stop site prior to the poly-glutamine stretch of ataxin-3. To create a single UIM construct
of just the N-terminal UIM194-244, the same approach was executed by using site directed
mutagenesis to make a stop site prior to the DNA sequence encoding the second UIM.
The individually intact UIM genes were synthesized by DNA2.0 in their house
pJexpress414 vector and cloned into the NdeI and XhoI sites (Fig. 2.1). The conserved
serine, (residues 236, 256 and 347 within UIM1, 2, and 3) and hydrophobic stretch in the
core UIM sequence (residues 229-243, 249-253, 340-344) were substituted to alanine
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residues and designed in the computer program Gene Designer 2.0. All genetic
elements were identical to the wild-type ataxin-3 constructs mentioned above. Three
vectors were ordered to experiment with individual functional UIMs; functional knockout
of UIM I/II, functional knockout of UIM II/III, and functional knockout of UIM I/III.
DNA sequencing was carried out to ensure the correct sequence of the ataxin-3 UIM
genes (Robarts Research Institute).

2.2.3

Expression and purification of the parkin ubiquitin-like domain
The human parkin UbLD was overexpressed in BL21(DE3) Codon PlusRIL

Escherichia coli strain and was cloned without an affinity tag. The bacterial culture was
diluted 1:100 volume ratio in LB media, and grown at 37°C until an A600 of 0.6-0.7 was
reached. The culture was grown with constant shaking overnight at 16°C after induction
of expression by the addition of 1 mM isopropyl 1-thio-β-D-galactopyranoside. The
starter culture and large bacterial cultures contained the antibiotic ampicillin (50 µg/mL).
Cells were lysed with either an EmulsiFlex-05 homogenizer (AVESTIN) or French press
and centrifuged at 132380 g for one hour. The cell homogenate was filtered through a
MILLEX HV 0.45 µm filter unit (MILLIPORE) before loading onto a HiTrap Q XL
column, using a AKTA FPLC system (GE Healthcare). The binding buffer contained 25

A
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Hexa-his Tag

E coli RBS
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Site
Multiple Cloning Site
<Optimized for E coli>
(Nde I, XhoI)

T7/lac
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(DNA 2.0)
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Figure 2.1 Diagrammatic representation of the DNA 2.0 pJexpress414
vector. The individually intact UIM genes were inserted into the NdeI and XhoI
sites of the pJexpress 414 vector. The genetic elements such as the hexa-His tag
and the TEV cleavage site matches the genetic elements for all the previously
mentioned ataxin-3 protein constructs. The multiple cloning site was optimized
for E. coli expression. All of the genetic elements and multiple cloning site
sequence were designed in the computer program Gene Designer 2.0.
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mM Tris and 1 mM EDTA at pH 9.0, and the elution buffer contained 25 mM Tris, 1
mM EDTA and 1 M NaCl at pH 9.0. The protein eluted in the flowthrough fractions and
was further purified on a size exclusion column (G75) at 4°C in 50 mM Na2HPO4, 150
mM NaCl, 1 mM EDTA, 1 mM DTT, at pH 8.0 with a flowrate of 6ml/hour. The
integrities of all ARJP substituted proteins were confirmed previously using electrospray
ionization mass spectrometry (UWO Biological Mass Spectrometry Laboratory) (2).

2.2.4

Expression and purification of ataxin-3 ubiquitin interacting motifs
All six human ataxin-3 UIM constructs were overexpressed in a BL21(DE3)

Codon PlusRIL Escherichia coli strain. The bacterial culture was diluted 1:100 volume
ratio in LB media, and grown at 37°C until an A600 of 0.6-0.7 was reached. The culture
was grown with constant shaking overnight at 16°C after induction of expression by the
addition of 1 mM isopropyl 1-thio-β-D-galactopyranoside. The starter culture and large
bacterial cultures contained the antibiotic ampicillin (50 µg/mL). Cells were lysed with
either an EmulsiFlex-05 homogenizer (AVESTIN) or French press and ultracentrifuged
at 132380 g. The cell homogenate was filtered through a MILLEX HV 0.45 µm filter unit
(MILLIPORE) before loading onto a Ni-NTA fast protein liquid chromatography affinity
column (GE healthcare). The loading buffer contained 50mM Na2HPO4, 500nM NaCl,
10mM imidazole at pH8, and the elution buffer was identical except with the addition of
500mM imidazole. The protein samples were dialyzed overnight at 4°C in the loading
buffer with an addition of TEV protease (1.2mg/1L bacterial preparation) for cleavage,
and reloaded onto the Ni-NTA column. Cleaved UIM proteins came off in the
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flowthrough. All six of the ataxin-3 UIM constructs were purified using the same
protocol.

2.2.5

NMR Spectroscopy titration experiments
All 1H-15N Heteronuclear Single Quantum Coherence (HSQC) NMR experiments

were performed on a 600 MHz Varian Inova spectrometer (BioNMR Facility, UWO). All
protein samples were extensively dialyzed into 11 mM KH2PO4, 150 mM NaCl, 1 mM
EDTA, 1 mM dithiothreitol, at pH 7. Imidazole (100 µM) was added in the final NMR
sample to serve as a pH indicator. All spectra were recorded at 25°C. Chemical shift
perturbation upon binding between protein samples were monitored and fit with either a
non-linear regression global fit for a 1:1 binding model or a 3:1 multivalent global fit
with equivalent affinities.

Consider,
! +   ! ⇌ !"
P - protein
L - ligand
PL - protein-ligand complex
The equation that was used for non-linear regression global fitting for a 1:1 binding site
was,
!" =   

(!" + ! + !! ) −

(!" + ! + !! )2 − (4 + ! + !")
2
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! = ! ∙ ! ∙ (!" !")
PL - Protein-Ligand Complex
Pt - Total Protein
X - Added Ligand Concentration
KD - Dissociation Constant (same units as Pt)
n - number of identical sites
B - Normalization Factor
The normalization factor is required for the global fit of the binding curves. Since the
chemical shift differences of different resonances that change upon addition of ligand are
not identical.

For a 3:1 multivalent model, consider,
! +   ! ⇌ !!!

K1

! +   ! ⇌ !!!

K2

! +   ! ⇌ !!!

K3

Where PL1, PL2, PL3 are three different sites on the ligand (ataxin-3) that the protein can
bind.
P - protein
L - ligand
PLx - protein-ligand complex

Assuming the ligand binds to each site with equal affinity (ie. K1 = K2 = K3 = KD), then
the equation used to globally fit a three multi-site binding model is,
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!" =

! ∙ !" + ! ∙ ! + !! −

(! ∙ !" + ! ∙ ! + !! )2 − (4 ∙ !2 ∙ ! ∙ !")
2 ∙ !2

! = ! ∙ ! ∙ (!" !")

The computer programs used to fit data were Prism 4 and NMRViewJ version 8.0.rc4.
Titration experiments that were performed are listed (Table 2.1). Protein samples were
sent to the Amino Acid Analysis facility (Sick Kids Hospital, Toronto, ON) for acquiring
accurate protein concentration values. Details regarding the concentrations of 15N-labeled
proteins as well as titrant proteins can be found in the results section.
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Table 2.1 The protein combinations used in the 1H-15N HSQC titration experiments
15

N Isotopically Labeled

Unlabeled Protein (Titrant)

Parkin UbLD

Ataxin-3 UIM123 194-361

Parkin UbLD

Ataxin-3 UIM12 194-261

Parkin UbLD

Ataxin-3 UIM1 194-244

Parkin UbLD

Ataxin-3 UIM3*194-361

Parkin UbLD

Ataxin-3 UIM2*194-361

Parkin UbLD

Ataxin-3 UIM1*194-361

Ataxin-3 UIM123194-361

Parkin UbLD

Ataxin-3 UIM12194-264

Parkin UbLD

Ataxin-3 UIM123194-361

Ubiquitin

* - indicates the ataxin-3 UIM constructs that are full-length (including residues 194361) but with only one functional UIM with the other two UIMs are ‘functionally
knocked out’ by alanine substitutions. In this context, functional is defined as being able
to retain interaction with the UbLD. In contrast, ‘functionally knocked out’ means that
conserved residues in the UIM sequence have been substituted by alanine residues and
can no longer interact with the UbLD.

37

2.3

Results

2.3.1

Molecular biology, expression and purification of parkin ubiquitin like domain
The human parkin UbLD gene had previously been inserted into the NdeI and

BamHI sites of the pET44a vector (Novagen) (3). The overexpression of the UbLD in
BL21(DE3) Codon PlusRIL Escherichia coli strain was induced with 1mM IPTG and the
overexpressed protein band can be seen just below the 10 kDa molecular weight ladder,
as expected since the molecular weight of the UbLD is 8824 Da (Figure 2.2). The rate of
protein separation of the sizing column was 6ml/hr and the fractions containing pure
UbLD protein elutes from the column between hours 65-75 or shown as lanes 7-10 in
Figure 2.2B. Purified proteins were checked on an SDS-PAGE gel for purity.

2.3.2

Molecular biology, expression, and purification of ataxin-3 UIM123194-361 and

other ataxin-3 constructs
The ataxin-3 UIM123194-361 construct with three intact UIM regions was
successfully inserted into the BamHI and XhoI sites of the pET21a vector (Novagen),
previously done. Site-directed mutagenesis was then used to incorporate a TEV cleavage
site to allow for the removal of a 6-residue N-terminal histidine tag from ataxin-3
construct.
All of the ataxin-3 protein constructs were overexpressed in a BL21(DE3) Codon
PlusRIL Escherichia coli strain. All ataxin-3 protein constructs have the same genetic
elements, an N-terminal six histidine-tag followed by a TEV cleavage site upstream of
the ataxin-3 UIM gene. Two Ni2+-NTA FPLC column steps were completed to obtain a
tag free protein that just includes pure fractions of ataxin-3 UIMs (Figure 2.3). In
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Figure 2.2 SDS-PAGE of parkin ubiquitin-like domain expression
and purification. A) Lanes 1 and 2 are the pre-induction and post IPTG
induction expression test for the UbLD. Lane 3 is the lysate, prior to
loading onto the HiTrap Q XL column and lane 4 is the flow through off
the column. Lane 5 is the molecular weight ladder. Lane 6 is the elution
fraction off the Q XL column. Lanes 7-9 show fractions collected from
the G75 sizing column. B) The SDS-PAGE of protein fractions collected
off of the G75 sizing column. The UbLD, which has a calculated
molecular weight of 8824 kDa, migrates just below the 10kDa molecular
ladder band. Both gels were stained in Coomassie brilliant blue.
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Figure 2.3 Purification of ataxin-3 UIM123194-361. A) The three lanes are showing
the first elution fractions off of the Ni2+-NTA column of the ataxin-3 purification,
prior to TEV cleavage of the hexa-histidine tag. The yellow arrow indicates the
overexpressed His-tagged ataxin-3 UIM123194-361 protein. B) SDS-PAGE showing
the elution fraction of the second part of the ataxin-3 purification. This fraction was
eluted from the second Ni2+-NTA column pass through, following TEV cleavage
overnight. C) The lane highlighted in the red box is showing the degradation of
ataxin-3 UIM123194-361 construct over two weeks time at 4°C.
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between the two Ni2+-column steps, the protein was extensively dialyzed in a low
imidazole buffer with TEV specific protease to cleave the N-terminal six histidine tag
from the ataxin-3 protein construct. His-tagged ataxin-3 UIM123194-361 migrates to
greater than 25 kDa, but after the TEV cleavage step, the ataxin-3 UIM123194-361 protein
migrates just short of 25 kDa (Figure 2.3). After purification of the ataxin-3 UIM region,
it was observed that this region was prone to degradation (Figure 2.3).

2.3.3

Ataxin-3 UIM123194-361 confers a docking site on the hydrophobic patch of the

parkin UbLD
Titration experiments monitored by 1H-15N HSQC spectra were performed with
15

N-labelled parkin UbLD and unlabeled ataxin-3, to identify the binding site of ataxin-3

on the UbLD. The 1H-15N HSQC spectrum of

15

N UbLD in the absence of binding

partner displays disperse peaks in the proton dimension, indicative of a well-folded
protein. Each peak represents the amide proton correlated to its amide nitrogen, thus,
each amino acid in the sequence, except proline residues, will have a corresponding
resonance. Resonances that shift upon titrations of a binding partner are indicative of
nuclei experiencing a local environmental change, which are the residues involved in the
interaction. The binding site on parkin was determined by measuring the absolute change
in chemical shift (in ppm) of the UbLD resonances with titrations of up to 6 equivalents
of ataxin-3 UIM123194-361 construct (Figure 2.4). The resonances that shifted greater than
0.5 standard deviation above the average chemical shift were mapped on the surface of the
UbLD (Figure 2.5). The backbone assignments of both parkin UbLD and most residues of
the ataxin-3 UIMs construct were previously determined, and all of the resonances were

Δ Chemcial Shift (ppm)
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Figure 2.4 NMR chemical shift perturbation data of parkin UbLD upon
ataxin-3 UIMs194-361 binding. Chemical shift perturbation map of UbLD by
measuring the absolute change in magnitude of the peak shifts that occurs after
addition of 6 eq. of ataxin-3. The concentration of the UbLD protein sample was
105 µM. The absolute change in magnitude of the resonance shifts were
calculated using the equation, ((0.2 × ΔδN2) + ΔδH2)1/2. The dotted green line
indicates 0.5 S.D. above the average chemical shift perturbation value. The
residues on parkin that display more than 0.5 standard deviation above the average
chemical shift are V3, N8, H11, F13, V15, A46, K48, E49, V56, I66, V67, H68,
V70, Q71, and R75.
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Figure 2.5 Surface and ribbon representation of the binding surface for ataxin3194-361 on the parkin ubiquitin like domain. A) A surface representation, coloured
in pink, of where ataxin-3194-361 binds on the UbLD. The residues that displayed more
than 0.5 standard deviation above the average chemical shift were mapped on the
surface of the UbLD which is highlighted in pink. B) The seven amino acid side
chains that displayed the greatest chemical shift perturbations upon addition of 6
equivalents of the full UIMs ataxin-3 construct are shown. The individual beta
strands and alpha helices from the beta-grasp fold blanketing over the alpha helix are
labeled.
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accounted for when a standard 1H-15N HSQC spectra of the UbLD1-77 and ataxin-3
UIM123194-364 construct were collected (3). The residues on parkin that display greater
than 0.5 standard deviation above the average chemical shift were Val3, Asn8, His11, Phe13,
Val15, Ala46, Lys48, Glu49, Val56, Ile66, Val67, His68, Val70, Gln71, and Arg75 (Figure 2.4).
Most of these residues are found on the solvent exposed hydrophobic patch of the UbLD,
as highlighted in pink (Figure 2.5). Ala46 and Ile66 are two of the hydrophobic residues on
the hydrophobic patch of parkin that are influenced by ataxin-3 UIM123194-361 binding.
From the perspective of the parkin protein, residues participating in the interaction are
dominated by hydrophobic amino acid residues (Leu61, Ile66, Phe13), followed by basic
amino acid residues (Lys48). The binding site on the UbLD is composed of residues from
multiple secondary structures, suggesting that the three-dimensional fold of this domain
must be intact to expose the docking site for ataxin-3.

2.3.4

Parkin UbLD interacts with all three ubiquitin interacting motifs from ataxin-3
1

H-15N HSQC titration experiments were utilized to investigate which UIM from

ataxin-3 participates in the interaction with the UbLD. For each NMR titration
experiment, 6-8 titration points were collected by incrementally adding unlabeled UbLD
to

15

N-labeled ataxin-3 UIM123194-361. At each titration point, a standard 1H-15N HSQC

experiment was collected. By overlaying the spectra taken from each titration point, the
resonances that were ‘shifting’ on the ataxin-3 could be identified. Many NMR titration
experiments were utilized to systematically identify whether UIM1, UIM2 and/or UIM3
participate in the interaction with parkin. However, the experiment involving 15N-labeled
ataxin-3 UIM123194-361 titrated with unlabeled UbLD1-77 was the only experiment that
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revealed whether any or all of the three UIM regions of ataxin-3 were interacting with
the UbLD.
The backbone assignments of the ataxin-3 UIMs construct were previously
assigned, by previous graduate student Dr. Safadi, and all of the resonances were
accounted for when collecting a standard 1H-15N HSQC spectra of the ataxin-3
UIM123194-361 construct. The dissociation constant from the perspective of each UIM
were globally fitted to a 1:1 non-linear regression fit, KD, UIM1= 2092±654 µM, KD, UIM2=
1071±263 µM, KD, UIM3= 1975±368 µM (Figure 2.6). The dissociation constant for UIM1
is in the same range within error for both KDs of the other two UIMs. Meanwhile, the KD
between UIM2 and UIM3 are not in the same range within error, with UIM2 having a
slightly tighter binding to the UbLD than UIM3. The KD values were calculated solely
based on the amide proton shifts, due to the greater magnitude of perturbation in the
proton dimension as compared with nitrogen dimension (Figure 2.7). However, there was
difficulty finding appropriate resonances from each UIM to measure chemical shifts
from, due to the collapse of many resonances in the proton dimension of the 1H-15N
HSQC spectrum of ataxin-3 UIM123194-361 protein alone, which is indicative of random
coils in protein fold (Figure 2.7). From UIM1, residues A232, A234, D241 were
followed, while in UIM2 only one residue (D248) could be unambiguously followed. In
UIM3, amino acid residues S335, V344, and T345 were followed to obtain the KD
(Figures 2.6, 2.7). Despite the collapse in the proton dimension of the spectrum, there are
still other resonances from each UIM that are clearly identified to be shifting in response
to additions of UbLD protein (Figure 2.7). The individual binding affinities of the UIM
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Figure 2.6 Binding curves of the change in proton chemical shift of
resonances from UIM1, UIM2, and UIM3 of ataxin-3 with titrations of
parkin UbLD. Measurements were taken from NMR 1H-15N HSQC titration
experiments with samples containing 15N ataxin-3 UIM123194-‐361 (73µM) and
additions of unlabeled UbLD (0, 58.7, 117.5, 235, 376, 470, 705, 940µM). The
KD values are KD,UIMI = 2092±654 µM, KD,UIM2 = 1071±263 µM, and KD,UIM3 =
1975±368 µM based on a global fit of non-linear regression analysis for 1:1
binding. The corresponding amino acid residue of which the chemical shifts
were measured are indicated to the right side of the binding curve.
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Figure 2.7 Region of the 1H-15N HSQC spectrum of ataxin-3 UIM123194-361
overlaid with a 1H-15N HSQC spectra of ataxin-3 UIM123194-361 with 12
equivalents of parkin UbLD (blue). NMR data was collected with Varian
INOVA 600 MHz NMR spectrometer with samples in a buffer containing 10 mM
KH2PO4, 1 mM EDTA, 1 mM DTT pH 7.0 at 25°C (pH indicator, Imidazole). The
starting concentration of 15N labeled ataxin-3 UIM123194-361 was 73µM and was
titrated with up to 12 equivalents of UbLD. The red arrows indicate the direction
of chemical shift changes upon UbLD additions for residues in UIM3. The yellow
and green arrows indicate chemical shifting directions for UIM2 and UIM1,
respectively.
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regions are all in the millimolar range suggesting that UIM1, UIM2 and UIM3 are all
able to make weak interactions with the UbLD.
The same experiments were repeated except with a

15

N-labelled species of the

ataxin-3 UIM12194-261 construct (containing only UIM1 and UIM2) with incremental
titrations of the UbLD to greater than 10 equivalents. The fitting of the binding curve was
poor due to not reaching saturation in binding of the isotopically labeled protein. The
binding affinity for both UIM1 and UIM2 were in the same range within error of all three
UIMs in the

15

N ataxin-3 UIM123194-361 experiment, mentioned above. The dissociation

constants were derived from considering chemical shift changes only in the proton
dimension, amino acid residues from UIM1 used to obtain a KD, UIM1 = 3075±563 µM,
were A232, A234, D241, residues from UIM2 to obtain a KD, UIM2 = ~15400±20000 µM,
were solely based on residue D248. The deletion of the most C-terminal UIM and polyglutamine tract (14Q) clears up some of the congestion of resonances in the proton
dimension of the 1H-15N HSQC spectrum. When comparing the ataxin-3 UIM12194-261
spectrum with the ataxin-3 UIM123194-361 spectrum, many of the residues belonging to the
third UIM or closely surrounding the motif, which are resonances that can only be found
in the ataxin-3194-361 1H-15N HSQC spectrum, can be observed to experience chemical
shift perturbations upon addition of the UbLD. Thus, the third UIM is participating in the
interaction with the UbLD, along with UIM1 and UIM2.
2.3.5

1

H-15N HSQC experiments of 15N parkin UbLD with titrations of individually

intact ataxin-3 support that all three UIM regions are able to interact with the UbLD
To support the findings from the titration experiments involving

15

N-labelled

ataxin-3194-361 and UbLD additions, which showed that all three UIM regions were
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participating in the interaction with the parkin UbLD, the complementary experiments
were carried out. This involved overexpressing the individual functional UIM regions,
and titration of these proteins into

15

N-labelled UbLD. The conserved serine and 5

hydrophobic core residues, both within the UIM region, were substituted for alanine
residues to ensure that the UIM was no longer able to bind to the parkin UbLD.
Comparisons of the UbLD 1H-15N HSQC spectrum alone overlaid with a 1H-15N HSQC
spectrum of the UbLD with an addition of the most concentrated addition of ataxin-3194361

intact UIM1, UIM2 and UIM3 shows that there were many similarities between the

resonances that experience a change in its chemical shift (Figures 2.8, 2.9, 2.10). Lys48,
Glu49, and Ile66 displayed the greatest chemical shift change upon binding to the ataxin-3,
and the corresponding resonances were consistently shifting in the same direction for
each separate titration experiment for additions of either intact UIM1, UIM2, or UIM3
constructs (Figure 2.9ADG, Figure 2.10). There were only local changes to the UbLD
upon binding each UIM, as only a few residues shift upon titrations of UIM1, 2 or 3.
Most of the resonances from the UbLD did not change upon titration of any of the UIM
regions (Figure 2.8). One such resonance was Val29, which is buried beneath the betagrasp fold, was not perturbed by complex formation. It is proximal to Val17, another
residue that was not perturbed greatly by complex formation with the UbLD (Figure
2.9CFI). Although most of the residues of the UbLD behaved similarly upon UIM1, 2 or
3 titrations, not all of the peaks shifted in identical magnitudes or direction (Figures 2.8,
2.10). The absolute chemical shift perturbations were measured to derive the dissociation
constant for each titration experiment. The dissociation constants were KD, intact UIM1 = 840
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Figure 2.8 1H-15N HSQC spectra of 15N parkin UbLD overlaid with spectra
following additions of functionally intact ataxin-3 UIM1*194-361 (A), UIM2*194-361
(B), and UIM3*194-361 (C). NMR data was collected with Varian INOVA 600 MHz
NMR spectrometer with samples in a buffer containing 10 mM KH2PO4, 1 mM
EDTA, 1 mM DTT pH 7.0 at 25°C (pH indicator, Imidazole). The starting
concentration of 15N labeled parkin UbLD was 100µM (for all three titrations) and
was titrated with up to (A) 6.5, (B) 8, (C) 7.9 equivalents ataxin-3, respectively.
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Figure 2.9 Selected region of 1H-15N HSQC spectra of 15N parkin UbLD
overlaid with HSQC spectra with incremental additions of functionally intact
ataxin-3 UIM1*194-361 (A-C), UIM2*194-361 (D-F), and UIM3*194-361 (G-I). Spectra
were collected on a Varian INOVA 600 MHz NMR spectrometer with samples in a
buffer containing 10 mM KH2PO4, 150 mM NaCl, 1 mM EDTA, 1 mM DTT pH 7.0
at 25°C (pH indicator, Imidazole). The starting concentration of 15N labeled parkin
UbLD was 100 µM (for all three titrations) and was titrated with up to (A) 6.5, (B) 8,
(C) 7.9 equivalents ataxin-3, respectively. The similar behaviour for resonances of
amino acid residues Lys48, Leu61 and Val29 for all three sets of titration experiments
is shown.
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Figure 2.10 NMR chemical shift perturbation data comparison of the parkin UbLD
interaction with individual functional ataxin-3 UIM1*194-361 (black), UIM2*194-361
(blue), and UIM3*194-361 (red). Chemical shift perturbation data of the UbLD was
determined by measuring the absolute change in magnitude of peak shifts that occurred
after addition of 6 eq. of ataxin-3. The absolute change in magnitude of the resonance
shifts were calculated using the equation, ((0.2 × ΔδN2) + ΔδH2)1/2. The dotted line
indicates 0.5 S.D. above the average chemical shift perturbation value. The residues on
parkin that display more than 0.5 standard deviation above the average chemical shift were
K48, E49, I66, and H68.
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± 189 µM, KD, intact UIM2 = 502 ± 41 µM, KD, intact UIM3 = 921 ± 165 µM (Figure 2.11).
The absolute chemical shifts were measured following residues Lys48, Glu49 and Leu61
for each titration experiment in order to generate binding curves. Other residues observed
to shift were Val43, Glu64, and His68; corresponding experiment for which these residues
were measured are found on Figure 2.11. The data collected from these three titration
experiments support the finding that all three UIM regions of ataxin-3 are participating in
the interaction with the UbLD.

2.3.6

1

H-15N HSQC experiments of UbLD with titrations of C-terminal deletions of

UIM regions display an increase in binding affinity when all three UIM regions are
present
Resonances of the 15N UbLD displaying the greatest chemical shifts in the 1H-15N
HSQC spectrum were measured (Figure 2.12, 2.13). After plotting the changes in
chemical shift in response to increased concentrations of C-terminal deletion ataxin-3
constructs, the dissociation constants were determined by a global fitting of the nonlinear regression analysis for a 1:1 binding curve.
The dissociation constants obtained for the full UIM construct to 15N UbLD were
235.7 ± 14.0 µM, and 221.7 ± 17.6 µM, in the nitrogen and amide proton dimension,
respectively (Figure 2.13A). The interaction appears to be weaker when the third UIM is
deleted, the KD values obtained for the ataxin-3 UIM12194-261 construct titrated into the
15

N UbLD were 422.5±25.8 µM, and 433.7±37.3 µM, in the nitrogen and amide proton

dimension, respectively (Figure 2.13B). When only the most N-terminal UIM is available
to interact
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Figure 2.11 Binding curves of the absolute change in chemical shift of 15N
UbLD with titrations of ataxin-‐3	
  UIM1*194-‐361,	
  UIM2*194-‐361,	
  and	
  
UIM3*194-‐361. The absolute chemical shifts take into consideration both the
proton and nitrogen chemical shifts. The KD values are KDUIMI = 840.3±188.6
µM, KDUIM2 = 502.3±41.4 µM, and KDUIM3 = 921.0±165.0 µM based on a global
fit of non-linear regression analysis for 1:1 binding. The corresponding amino
acid residue of which the chemical shifts were measured are indicated to the
right side of the binding curve.	
  

	
  

	
  

Figure 2.12 Close-up view of overlaid HSQC spectra of 15N UbLD titrated with ataxin-3 (A) UIM123194-361, (B) UIM12194-261
and (C) UIM1194-244. NMR data was collected with Varian INOVA 600 MHz NMR spectrometer with samples in a buffer
containing 10 mM KH2PO4, 1 mM EDTA, 1 mM DTT pH 7.0 at 25°C (pH indicator, Imidazole). The starting concentration of 15N
labeled parkin UbLD was 105µM, 100µM, 40µM and was titrated with up to 6, 5, 10 equivalents ataxin-3, respectively. The
arrows indicate the direction of peak shifts upon increasing the ataxin-3 concentration.
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Figure 2.13 Binding curves determined by the change in
chemical shift of the nitrogen dimension only, for 15N UbLD
with incremental titrations of (A) UIM123, (B) UIM12, and
(C) UIM1. The KD values are KDUIMI23 = 235.7±14.0 µM, KDUIM12
= 422.5±28.5 µM, and KDUIM1 = >2000±400 µM based on a global
fit of non-linear regression analysis for 1:1 binding. The
corresponding amino acid residues of which the chemical shifts
were measured are indicated to the right side of the binding curve.
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with the UbLD, the KD was greater than 2 mM with a standard error of 400 µM (Figure
2.7C). The poor fit of the binding curve can be attributed from not being able to saturate
the UbLD with enough substrate. Another difficulty that arose was due to resonance
behaviour, such as peak intensity changes, which made it difficult to distinguish the peak
above noise of the HSQC. Therefore, some peaks could not be unambiguously assigned
in order to track the changes in chemical shift. An example of this behaviour was seen by
Arg75 (Figure 2.13C). The only residue that could be unambiguously followed for UIM1
construct and gave the best fit was Lys48 (Figure 2.13C).
Most of the residues that displayed large chemical shift changes are located on the
fourth and fifth β-strand, such as Lys48 and Glu49 on the fourth β-strand, and Gln64, Ile66
on the fifth β-strand. Other residues outside this region that shifted include residues
Phe13, which resides at the N-terminus (2nd β-strand), and Arg75 located at the C-terminus
tail of the UbLD. While these residues are not clustered in exactly the same regions, they
all fall on the beta-grasp face of the UbLD (Figure 2.5).

2.3.7

Modelling the binding mechanism of the ataxin-3 UIM123194-361 with UbLD using

a multivalent binding mechanism
The observations that all three UIM regions were participating in the interaction
with parkin and that the greater the number of intact UIM regions correlates with
strengthening the interaction led to the prediction that a multivalent binding mechanism
could be employed by the UIM domains in ataxin-3. A new model was designed to fit the
binding curves and accomodate for a three-site binding mechanism, under the assumption
that all the binding sites have equal affinities to the UbLD. The resulting KD was
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calculated to be 669±62 µM and 725±43 µM in the proton and nitrogen dimension,
respectively (Figure 2.14).

2.4

Discussion
1

H-15N HSQC titration experiments were used to determine the binding site of the

ataxin-3 UIM123194-361 protein construct on the UbLD. To ensure that the chemical shift
perturbations were due to protein interactions and not residues that are susceptible to pH
changes, imidazole was added as a pH indicator to all of the NMR samples. Confidence
in the reliability of the data can be based on four observable traits in the HSQC spectra;
linear peak shifting, no systematic peak shifting is occurring, the peak shifts of different
residues are in different directions, and the center of each peak is easily measurable and
able to be followed (Figures 2.9, 2.12).
2.4.1

The UIM regions of ataxin-3 interacts with the hydrophobic patch of the UbLD
1

H-15N HSQC titration experiments of

15

N UbLD with up to a 6 equivalent

addition of ataxin-3 UIM123194-361 revealed that most of the interacting residues reside on
the solvent exposed surface of the beta-grasp fold of the UbLD, highlighted in pink
(Figure 2.5). This region of interaction is similar to the interaction shown between the
ataxin-3 UIM123194-361 bound to ubiquitin molecules (7). Like the UbLD interaction, the
UIM region confers a docking site on the hydrophobic patch of Ub, centered on Leu8,
Ile44, Lys48 and Val70 (7). When comparing the chemical shift perturbation map of 15N Ub
vs. 15N UbLD

! Chemical Shift 1H (ppm)
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Figure 2.14 Binding curves of proton and nitrogen changes in chemical shift
of 15N UbLD with titrations of ataxin-3194-361. The KD values are 668.7±61.70
µM and 724.8±42.66 µM in the proton and nitrogen dimension, respectively. The
fitting is based on a multisite non-linear regression analysis for 3:1 binding, with
three equivalent affinity sites. The corresponding amino acid residues of which
the chemical shifts were measured are indicated to the right side of the binding
curve.
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upon ataxin-3 binding, plotting the magnitude of chemical shift as a function of the
residue position, the overall trends in which residues shift the greatest are almost identical
(for example positions 8-13, 46-49, and residues at the C-terminus of both proteins) (7).
The binding site on the UbLD and Ub is complementary to the UIM region of ataxin-3,
which is composed of an acidic stretch of 3-4 residues followed by a hydrophobic core of
typically 5 amino acid residues. Based on affinity binding assays the third UIM was
found to not participate in the interaction to Ub and the KD of the Ub to ataxin-3
UIM12194-261 interaction is just below 100 µM, which is relatively tight binding in the
scope of UIM to UbLD binding interactions (7). The interaction between ataxin-3 and Ub
is important for surveillance of its substrate proteins. Since ataxin-3 is a DUB enzyme, it
is able to edit ubiquitin chains, preferably Lys63 Ub linkages important in DNA repair
pathways, or specific substrates that require its surveillance (8). The biological
importance of the interaction between ataxin-3 and the parkin UbLD is not well
estabilished. Recently, ataxin-3 has been found to divert E2-Ub from parkin
ubiquitylation by forming a stable complex between the E2, parkin, and ataxin-3, causing
the ataxin-3 protein to become ubiquitylated (9). This is not the conventional deubiquitylating mechanism, and ataxin-3 was originally thought to detach distal Ub
moieties from a Ub-chain, though it is interesting that this mechanism is specific to
parkin and could potentially rely on the UIM UbLD interaction (9). Despite the
differences of biological importance in the interactions between Ub or UbLD to the UIMs
of ataxin-3, the same hydrophobic and basic face of the Ub or UbLD is utilized to contact
the UIM region.
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2.4.2

Parkin UbLD makes weak and direct interactions with the three UIM regions of

ataxin-3
The arrangement of UIM sites within ataxin-3 are unique because no other UIMcontaining protein has three motifs in the same topology as ataxin-3, which are all located
within the flexible C-terminal tail (10). A variable poly-glutamine tract separates the
second and third UIM, that when expanded to greater than 45 residues, causes the most
common dominantly inherited spinocerebellar ataxia. Meanwhile, UIM regions 1 and 2
are much closer with one another in the protein sequence. The ataxin-3194-361 protein
bound to the UbLD with a KD of ~230 µM, when the binding curves were globally fit
with a 1:1 non-linear regression curve (Figure 2.13). This relatively weak interaction was
expected, considering that other UIM-containing proteins such as Eps15 and S5a both
bind to the UbLD with KDs in the range of 100-200 µM (2). With the interaction of
ataxin-3 with UbLD proteins being transient in nature, these weak KD values are
biologically significant.

2.4.3

All three UIM regions of ataxin-3 participate in the interaction with parkin

The most compelling results to show that all three UIMs are participating in the
interaction to the UbLD were the NMR titrations of

15

N ataxin-3 UIM123194-361 with

UbLD additions and the reverse experiments of 15N UbLD with individually intact UIM
regions. Previous evidence has shown that the conserved serine, which is present amongst
all UIM sequences, is absolutely essential for the interaction with the UbLD and Ub (1,
12). To ensure that the UIM region has been ‘knocked down’ in its ability to interact to
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the UbLD, we substituted five core hydrophobic residues to alanine residues to abolish
interaction with the hydrophobic patch of the UbLD, and for preservation of the helical
nature of the UIMs (2). Alanine substitutions of two conserved regions, the serine and
five residue hydrophobic core both within the UIM sequence, provide confidence that the
interaction between the UIM and UbLD is abolished.
NMR titration experiments of

15

N UbLD with the C-terminal deletion ataxin-3

construct of UIM1194-244, as well as the titration experiments with ataxin-3 UIM1*194-361
provide evidence that supports that UIM1 is able to weakly bind to the UbLD (Figures
2.11, 2.12C). The binding affinity was in agreement for both titration experiments with a
KD value in the millimolar range. The observation that the binding affinities are in
agreement, provides confidence that the alanine substitutions of the conserved serine and
hydrophobic core of the UIM has lost its ability to interact with the UbLD.
Based on the NMR titration experiments of 15N UbLD with ataxin-3 UIM2*194-361,
the second UIM has the tightest affinity to the UbLD compared with ataxin-3 UIM1*194361

and ataxin-3 UIM3*194-361 (Figure 2.10). It is not clear why the second UIM has the

tightest binding affinity. Interestingly, previous evidence has shown that the opposite
trend occurs for interaction with a single ubiquitin moiety. The ataxin-3 UIM1 binds
tighter (KD = 215 µM) than UIM2 (KD = 309 µM), and UIM3 has the weakest affinity
(KD > 3000 µM) (7). The explanation for why one UIM has a higher preference to bind
the UbLD versus Ub or vice versa needs further investigation, however, in the scope of
binding affinities, these are all within the same relatively weak binding range.
The NMR titration experiments of the

15

N UbLD with ataxin-3 UIM3*194-361

additions, as well as the complementary experiment with 15N ataxin-3 UIM123194-361 both
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provide compelling evidence to support that the third UIM is participating in the
interaction. The 1H-15N HSQC spectra of

15

N ataxin-3 UIM123194-361 was difficult to

analyze due the overlap of peaks found in the proton dimension (7.7-8.8 ppm) which is
indicative of a random coil protein (13). Some of the residues that are nearby or within
the third UIM, S335, V344, and T345, could be tracked in the 1H-15N HSQC spectrum,
and showed clear chemical shift perturbation upon additions of up to 10 equivalents of
the UbLD (Figure 2.7). These same conserved residues are present within the third UIM,
so one may predict that it is also involved in the interaction based on sequence identity to
the N-terminal UIM regions. However, UIM interactions cannot be predicted based
solely on sequence similarity as seen for UIM containing protein S5a which only utilizes
its N-terminal UIM for interactions with parkin (1, 2).

2.4.4

Differential interactions of the parkin UbLD with UIM-containing proteins

Eps15, S5a and ataxin-3
In 2001, there were approximately 30 reported proteins containing the ubiquitin
interacting motif, and most of them contained more than one UIM (10). Since all UIMs
have conserved elements within their ~20 amino acid motif, there is likely a lot of
overlap in terms of which UIMs are able to bind to the UbLDs. The question then
becomes, how can the parkin UbLD recognize which protein it is interacting with if many
of its binding partners have UIMs? Two of the thirty identified UIM-containing proteins,
Eps15 and S5a, have been extensively studied for their differential interaction with the
parkin UbLD (2). K48, A46, and I66 are the hydrophobic residues on parkin that are
occupied by the UIM(s) of Eps15, S5a and ataxin-3. Residues V56 and V15 in parkin
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display large absolute chemical shift changes when ataxin-3 is added, whereas, in both
Eps15 and S5a’s docking site, these two particular residues do not display a peak shift
above the average shift (Figure 2.4) (2). Although, Eps15, S5a and ataxin-3 all contain
more than one UIM in the C-terminal tail of their respective full-length proteins, the
Eps15, S5a and ataxin-3 proteins behave very differently in their binding mechanisms to
the UbLD.
Eps15 utilizes two UIM regions to bind to the UbLD of parkin, meanwhile, S5a
only uses one UIM and there is a clear distinction that the amount of surface area that is
able to bind one UIM is less (9). Simply due to the number of surface residues displaying
large chemical shifts upon addition of the ataxin-3 UIM123194-361, there seems to be a
surface area that can accommodate one or two UIM regions simultaneously, but not three
simultaneously. Further investigation of the binding between the proteins suggests that
the third UIM is not a bystander in the interaction with parkin. The work presented here
has shown that although the ataxin-3 UIM123194-361 confers a docking site that is in the
same region where other UIM-containing proteins, such as Eps15 and S5a, bind to the
parkin UbLD, the mechanism of interaction for ataxin-3 may be unique compared to
Eps15 and S5a.

2.4.5

The UIM region of ataxin-3 employs a multivalent binding mechanism to interact

with the UbLD
The multivalent binding mechanism is characterized by multiple weak binding
sites that have fast off-rates, such that when the number of binding moieties increases, the
affinity of binding becomes tighter (16). There are many pieces of evidence to suggest
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that a multivalent binding interaction could be employed by the UIM region of ataxin3, one of which were the initial KD calculations between parkin and ataxin-3, which were
carried out with a simple 1:1 binding model, referred to as the macroscopic dissociation
constant. The preliminary analysis, from the ataxin-3 C-terminal deletion titration
experiments, showed that increasing the number of UIM regions also increases the
binding affinity to parkin. There was a tenfold increase in having the three UIM regions
present versus one (Figure 2.13). Rap80, a DNA repair protein reported to use
multivalent binding mechanisms to interact with ubiquitin chains, was found to have an
increased affinity with increasing poly-ubiquitin chain length (16). Interestingly, Rap80
has two tandem UIM regions and the discovery of how it binds to ubiquitin chains,
preferentially Lys63 Ub linkages, was through 1H-15N NMR titration experiments as well
as molecular dynamic simulations.
After close inspection of the data collected from the 1H-15N HSQC titration
experiments with the UbLD and various UIM constructs, a new multivalent binding
equation was derived. The model assumes that only a single UbLD can bind to a single
UIM site at one time point with equal binding affinities, which was validated from
considering the chance that two UbLD moieties could simultaneous bind was very
unlikely, that the affinities of each UIM interacting with the UbLD were similarily weak,
and that the docking site on the UbLD could accommodate one to two UIM sites. The
KDs derived from the multivalent 3:1 binding model were 668.7±62 µM and 724.8±43
µM in the proton and nitrogen dimension, respectively. Importantly, these KD values
were similar to the KD values derived from the experiments involving ataxin-3 UIM1*194361

, UIM2*194-361, and UIM3*194-361, which were 840.3±188.6 µM, 502.3±41.4 µM, and
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921.0±165.0 µM, respectively (Figure 2.11). The similarity between the two derived
KD values, fit with the appropriate 1:1 or multivalent 3:1 binding model, provides support
that the multivalent type of fit is appropriate for the chemical shift perturbation data when
the ataxin-3 UIM123194-361 construct is titrated into 15N UbLD.

2.4.6

Biological importance of the DUB enzyme and E3 ligase interaction
In 2010, the Fon group proposed that self-ubiquitinating E3 ligases have a

‘relationship’ with DUB enzyme(s) to prevent their own rapid turnover via the
proteasome. This has been seen for other E3:DUB pairs, such as MDM2:HAUSP, and
ITCH:FAM/USP9X (1,14). Recently, there has been evidence to supporting the
importance of the interaction of parkin and ataxin-3. Interestingly, ataxin-3 can be
ubiquitylated, preferentially at Lys117, which enhances its DUB catalytic activity in vitro
and in cells (15). Ataxin-3 was shown to preferentially deubiquitinate FLAG-parkin
ubiquitin chains versus free ubiquitin chains or ubiquitin chains on other RING E3
ligases such as SIAH and CIAP2 (1). As well, there is evidence to show that ataxin-3 has
a unique mechanism to prevent parkin from being ubiquitylated by sequestering an E2
(Ubc7) in complex with parkin and diverting the Ub moiety onto ataxin-3 itself (9). This
suggests that there is specificity in the DUB function of ataxin-3 for parkin. In addition,
cyclohexamide pulse-chase experiments, when the ataxin-3 polyglutamine tract is at a
disease relevant length (82Qs), causes parkin levels to drop in the cell due to increased
turnover by autophagy (1). All of these examples provide growing evidence to support
that ataxin-3 has a ‘partnership’ with parkin for interplay in regulating each other’s
function.
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In this work, NMR titration experiments were used to identify the binding site
that the UIMs of ataxin-3 confer on parkin UbLD, as well as, investigate the binding
mechanism and importance of the third C-terminal UIM. In identifying the site of
interaction on the UbLD, prediction of ARJP mutations that may be relevant for
disrupting the interaction to ataxin-3 is possible. Further, this work provides evidence that
the binding interface on parkin where the three UIMs of ataxin-3 interacts, lies on the
hydrophobic patch of parkin but provides unique contacts that have not been present in
Eps15 or S5a UIM to UbLD protein interactions (2). Individually, each UIM has a very
weak affinity for the UbLD, in the one millimolar range. The binding affinity is the
greatest when all three UIMs are intact and are available to interact with the UbLD.
Collectively, the results led to the prediction that there may be a multivalent binding
mechanism between the UIM region of ataxin-3 and the parkin UbLD.
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Chapter 3
STRUCTURALLY INTACT DISEASE STATE MUTATIONS WITHIN PARKIN
UBLD RETAIN INTERACTION WITH THE ATAXIN-3 UIM REGION

3.1

Introduction
Greater than 50% of Autosomal Recessive Juvenile Parkinsonism (ARJP) patients

have mutations attributed to the parkin gene (1). In the parkin Ubiquitin-Like Domain
(UbLD) alone, there have been 20 ARJP substitutions identified in 16 different amino
acid residue positions (2). This chapter provides analysis on a selection of these ARJP
single amino acid substitutions within the UbLD and interaction studies with ataxin-3.
Certain ARJP substitutions on the UbLD can compromise the interaction with the UIM
regions, as seen previously, with the UIM-containing protein S5a, which is a component
of the 19S regulatory subunit involved in proteasomal degradation (1). The loss of the
parkin-S5a interaction is proposed to result in impaired delivery of parkin ubiquitylated
substrates to the proteasome. This could be a source of pathogenesis to seed protein
misfolding diseases. This work aimed to determine what effect certain ARJP substitutions
would have on the interaction of the UbLD with the UIM containing region of ataxin-3.
However, the biological outcome of the disruption of the parkin UbLD interaction with
ataxin-3 is unknown. Currently, binding assays provide evidence to suggest that the
interaction between ataxin-3 and parkin is bimodal, with a second interaction site located
in the Josephin domain of ataxin-3 to the IBR-RING2 of parkin (3). It may be possible
that if the interaction between an ARJP mutant containing UbLD and ataxin-3 UIM
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region is compromised, the interaction between parkin and ataxin-3 may still exist
through the 2nd interaction site, the parkin IBR-RING2 and the Josephin domain.
The following ARJP substitutions were selected for study, UbLDV15M (4),
UbLDR33Q (5), UbLDA46P (6), and UbLDK48A (7). The ARJP substitutions were selected
because they have minimal affect on the three dimensional structure of the UbLD based
on extensive structural characterization by NMR spectroscopy and circular dichroism
spectropolarimetry (2). The only exception is UbLDA46P, which has been previously
shown to be unfolded (4). Secondly, these ARJP substitutions have been shown to
participate in the interaction or are nearby the interaction site between the UIM region of
ataxin-3 and the UbLD. Understanding the underlying mechanisms for the wildtype
interaction of parkin and ataxin-3, discussed in Chapter 2, are highlighted here by
showing how these disease relevant substitutions on parkin may compromise the
interaction to the UIM regions.
In this work, the aim was to investigate ARJP substituted UbLD proteins that are
structurally unaffected, to determine whether these mutations specifically alter the
interaction with ataxin-3. To address this objective the structures of several ARJP
substituted UbLD proteins (UbLDV15M and UbLDK48A) were assessed by NMR 1H-15N
HSQC titration experiments, and the interaction between ataxin-3 UIM123194-361 and
substituted UbLD proteins were investigated by an affinity binding assay and NMR
titrations. Lastly, the binding affinities were quantified by NMR titrations.
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3.2

Materials and Methods

3.2.1

Parkin ARJP substitutions within the UbLD
Parkin UbLD molecular biology details are described in Chapter 2. The ARJP

relevant mutants used for the interaction studies (V15M, R33Q, A46P, K48A) were
generated previously through using QuikChange Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA) (2). All constructs were expressed without fusion tags. The
mutant parkin UbLD constructs were verified by DNA sequencing (Robarts Sequencing
Facility).

3.2.2

Expression and purification of parkin ARJP substituted proteins
ARJP substituted UbLD constructs were overexpressed and purified as described

for the wildtype human parkin UbLD, described in Chapter 2. The integrity of all proteins
were confirmed by electrospray ionization mass spectrometry (2).

3.2.3

Expression and purification of ubiquitin
Human ubiquitin was overexpressed in the pLysS Escherichia coli strain. The

bacterial culture was grown as described for the parkin UbLD, with the exception that
induction of expression with the addition of 1 mM IPTG at an A600 of 0.4-0.5. Both the
overnight culture and the large growths of bacteria were grown in Luria-Bertani media
and contained ampicillin (50 µg/ml) and chloramphenicol (34 µg/ml). Cell lysis was
completed using flash freezing with liquid nitrogen and thawing, followed by sonication.
The cell homogenate was then spun at 132380 g for 60 minutes, the supernatant was
slowly brought to a pH of 3.5 and spun at 7378g. The supernatant was extensively
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dialyzed with 25 mM Tris, 1 mM EDTA, and 150 mM NaCl at pH 8, loaded onto a
G75 sizing column and eluted as described previously for parkin UbLD, Chapter 2.

3.2.4

ARJP substituted parkin UbLD binding assay with His-tagged ataxin-3

UIM123194-361
All pure protein samples were extensively dialyzed in binding buffer (20 mM
sodium phosphate, 10 mM imidazole, 300 mM NaCl, pH 8) prior to mixing the proteins.
Purified His-tagged ataxin-3 UIM123194-361 proteins were placed in an eppendorf tube on
a rotating mixer and incubated with either parkin UbLD, ARJP substitutions of the parkin
UbLD (K48A, A46P, R33Q, V15M), or ubiquitin, to give a final volume of 300 µL, at
4°C for one hour. Mixtures of 1:2 molar ratio His-tagged ataxin-3 construct:UbLD, (or
ubiquitin) were used; concentrations were determined by the BIO-RAD protein assay.
The principal behind this assay involves using the acidic Coomassie Brilliant Blue G-250
dye that changes color upon binding to protein, which can then be measured at an
absorbance of 595 nm by a spectrophotometer. Beer’s law is then applied to quantitate
the protein concentrations. Following incubation of the protein mixture, a total volume of
300 µL was loaded on a Ni-NTA spin column (Qiagen) and incubated for 3 minutes at
room temperature before being spun at 6 g. The column was washed twice with 600 µL
of binding buffer and eluted with the same buffer, but with 250 mM imidazole. Eluted
samples were separated by electrophoresis on a 16.5% tris-tricine polyacrylamide gel and
stained with Coomassie brilliant blue dye.
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3.2.5

NMR spectroscopy titration experiments
The

1

H-15N Heteronuclear Single Quantum Coherence (HSQC) NMR

experiments were performed with a 600 MHz Varian Inova spectrometer (BioNMR
Facility, UWO). All protein samples were extensively dialyzed into 11 mM KH2PO4, 150
mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, at pH 7 and 100 µM imidazole was added
in the final NMR sample to serve as a pH indicator. All spectra were recorded at 25°C.
Prism 4 and NMRViewJ version 8.0.rc4 were used to fit non-linear regression and global
fitting for a 3:1 multivalent binding model, derived from following chemical shift
perturbations upon titrating an unlabeled binding partner into the

15

N-labeled protein

species. Details about the equation used for the multivalent binding fit is included in the
Materials and Methods section of Chapter 2.

3.3

Results
ARJP-substituted UbLD proteins had similar yields of pure protein per litre of

bacterial growth compared to wildtype (WT) UbLD (approximately 10 mg), with the
exception of UbLDA46P which has approximately half the UbLDWT yield (~5 mg). The
purification protocol used for WT UbLD was also successful for purifying the ARJPsubstituted proteins, UbLDV15M, UbLDR33Q, UbLDA46P and UbLDK48A. This suggests that
the size and shape of all the UbLD proteins are alike and soluble, with the exception of
UbLDA46P, which may be prone to degradation, shown previously, or in the insoluble
fraction (2). Following purification, affinity binding assays and NMR titration
experiments were utilized to investigate whether structurally intact ARJP-substituted
UbLD proteins were able to sustain the interaction with the UIM region of ataxin-3.
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3.3.1

K48A and V15M ARJP substitutions in the UbLD retain their domain structure
1

H-15N HSQC experiments were used to determine whether any local or global

changes in structure occur, upon the ARJP substitutions UbLDV15M and UbLDK48A.
Comparisons of the spectra between the UbLDK48A and the UbLDWT showed no drastic
differences in spectral dispersion, as >80% of the resonances overlaid with the WT UbLD
resonance positions (Figure 3.1). The 1H-15N HSQC spectra of the UbLDV15M had less
overlap with the WT UbLD. Approximately 60% of the resonances overlaid with their
locations on the original WT UbLD 1H-15N HSQC, and the broad spectral dispersion in
the proton dimension was maintained (Figure 3.1). When comparing the UbLDK48A 1H15

N HSQC spectrum with the WT UbLD spectrum, there were approximately 5 peaks that

show a greater difference in resonance position compared to others including Leu26,
Gln64, Leu61, Trp74, and Arg75. These residues do not reside in the same region of the
UbLD. Leu61 is the closest in space with the Lys48 position. The remaining residues are
located much farther in 3D space to the Lys48 position. For example, Gln64 is located at
the N-terminus of the β5 strand, Trp74 and Arg75 are both located on the flexible Cterminal tail and Leu26 is on the α2 helix and has its side chain pointing towards the
inside of the beta grasp fold. The resonances that change upon substitution of V15M are
different than those seen in the K48A substituted UbLD. For example Leu61 changes its
resonance for both ARJP substitutions but the resonance was more upfield in the
UbLDK48A spectrum, meanwhile the Leu61 peak in UbLDV15M shifted more downfield
(Figure 3.1). Despite all the resonances that are altered upon a single amino acid
substitution, the peaks still remain well dispersed in the proton-dimension, and overlay
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Figure 3.1. 1H-15N HSQC spectra of wildtype (black) UbLD overlaid with
ARJP substituted UbLDK48A (blue) and UbLDV15M (red). The spectra were
collected on a Varian INOVA 600 MHz NMR spectrometer with samples in a
buffer containing 10 mM KH2PO4, 1 mM EDTA, 1 mM DTT pH 7.0 at 25°C (pH
indicator, Imidazole). The concentration of 15N labeled parkin wildtype UbLD
and ARJP substituted UbLDK48A samples were 100 µM, while the UbLDV15M
sample was 150 µM. The ribbon diagram of the UbLD highlights the position of
the substitution depicted with the original side chain colored blue (K48) and red
(V15).
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well with the WT spectrum. Overall, the chemical shift changes are small (<0.1ppm in
the proton dimension, and <2.0ppm in the nitrogen dimension) (Figure 3.1). This
suggests that the general domain fold was intact and similar to the UbLDWT, and only
local changes occurred after the introduction of the V15M and K48A substitutions.
3.3.2

Structurally intact ARJP substituted UbLD proteins can interact with ataxin-3

UIM123194-361
An affinity-binding assay was used to assess whether ARJP substitutions within
the UbLD can interact with ataxin-3 UIM123194-361. The ataxin-3 UIM123194-361 construct
contains a His-tag and was incubated with one of the UbLD proteins. After washing the
nickel column with the pre-loaded incubated protein samples, gel electrophoresis was
used to detect the presence the ARJP-mutant UbLD proteins from the eluted samples
(Figure 3.2). UbLDA46P and the UbLDWT were used as negative and positive controls in
the binding assay. The first three lanes in the gel show the Ni-NTA spin column elution
of His-tagged ataxin-3 UIM123194-361, UbLD, and Ub proteins alone. The elution fraction
of the mixtures of His-tagged ataxin-3 UIM123194-361 with Ub, UbLD, UbLDV15M,
UbLDR33Q, UbLDA46P and UbLDK48A are shown (Figure 3.2). The intensity of the WT
UbLD elution band was similar in intensity with UbLDV15M, UbLDR33Q, and UbLDK48A
for the mixtures with His-tagged ataxin-3 UIM123194-361. Loading amounts were the same
amongst the WT UbLD and UbLD variants (Figure 3.2). The elution of the UbLDA46P
and Ub band are fainter, indicating poorer binding. The His-tagged ataxin-3 UIM123194361

, indicated by a yellow arrow, has a similar protein band intensity at the same position

in the polyacrylamide gel to one another, just above 25 kDa (Figure 3.2).
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Figure 3.2. Affinity binding assay of the his-tagged ataxin-3 UIM123194-361 and
ARJP disease substitutions, UbLDV15M, UbLDR33Q, UbLDA46P, UbLDK48A,
wildtype UbLD and ubiquitin. The top panel is an SDS-PAGE showing the
elution of the Ni-NTA column for His-tagged ataxin-3 UIM123194-361 and various
UbLD species for an hour at room temperature. Mixtures of his-tagged ataxin-3
and UbLD, or ubiquitin in 1:2 molar ratios were used. Two washing steps were
carried out prior to the elution step. The yellow arrow is indicating the his-tagged
ataxin-3 UIMs protein band. The protein bands that are just below 10 kDa are the
non-tagged eluted UbLD or Ub species. The bottom panel is an SDS-PAGE of the
purified UbLD species from a 200 µM stock that was used in the binding assay.
The (+), indicates the positive control in the binding assay.
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The NMR titration experiments with

15

N-labeled UbLDK48A and UbLDV15M

showed that specific residues experience different chemical shift changes upon titration
with ataxin-3 UIM123194-361. Residues Phe13, Leu61, Gln64 and Ile66 all experience
changes in chemical shift in both similar magnitude and direction in both UbLDK48A and
UbLDV15M proteins (Figures 3.3, 3.4). In the titration experiment involving UbLDV15M,
Lys48 showed the largest chemical shift change in response to ataxin-3 UIM titrations.
The titration experiments involving 15N UbLDK48A, the resonance corresponding to Val15
also experiences a change in chemical shift (Figure 3.4). The V15M substitution resulted
in the methionine resonance to experience very minimal chemical shift perturbations,
originally shifting >0.5 ppm (Val15) in the nitrogen dimension to <0.2 ppm (Met15)
(Figure 3.3). The resulting substituted Ala48 could not be identified on the HSQC spectra,
as the backbone assignments for the UbLDK48A had not been completed. These results
suggest that both the Val15 and Lys48 positions are participating in the interaction with
ataxin-3 UIM region and the substitution of these residues has the potential to
compromise the interaction to ataxin-3.

3.3.3

K48A and V15M ARJP substituted UbLD proteins utilize the same binding

surface on the UbLD to interact with the UIMs of ataxin-3
Multiple resonances from the 1H-15N HSQC spectra of UbLDK48A and UbLDV15M
exhibit similar chemical shift perturbation behavior upon ataxin-3 additions. As
mentioned above, residues Ile66, Phe13, Leu61, and Gln64 all experience similar resonance
movement in both titration experiments (Figures 3.3, 3.4, 3.5). These are also the
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Figure 3.3 Select region of the 1H-15N HSQC spectra of 15N-labeled parkin
UbLDK48A (A) and UbLDV15M (B) overlaid following incremental additions
of ataxin-3 UIM123194-361. The starting concentration of 15N labeled parkin
UbLDK48A was 100 µM and UbLDV15M was 150 µM. The ARJP substituted
UbLD were titrated with up to four (A), and five (B) equivalents of unlabeled
ataxin-3 UIM123194-361, respectively. Resonances that exhibit similar behavior
(Phe13, Ile66 and Gln64) are highlighted (red) for both titration experiments.
Peaks are shifting from light colored to dark colored.
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Figure 3.4 Regions of 1H-15N HSQC spectra of 15N parkin UbLDK48A (A, B,
C) and UbLDV15M (D, E, F) overlaid with HSQC spectra of incremental
additions of ataxin-3 UIM123194-361. NMR data was collected on a Varian
INOVA 600 MHz NMR spectrometer with samples in a buffer containing 10
mM KH2PO4, 1 mM EDTA, 1 mM DTT pH 7.0 at 25°C (pH indicator,
Imidazole). The starting concentration of 15N labeled parkin UbLDK48A was 100
µM and UbLDV15M was 150 µM. The ARJP substituted UbLD was titrated with
up to four (A, B, C), and five (D, E, F) equivalents of unlabeled ataxin-3
UIM123194-361, respectively. This figure highlights the similar peak shifting
behavior for amino acid residues Leu61 and Gln64 for both titration experiments.
The V15 and K48 peak shifts are highlighted in the parkin UbLDK48A and parkin
UbLDV15M spectra, respectively.
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Figure 3.5 Chemical shift perturbation data and corresponding surface
representation of the wildtype parkin UbLD (A), UbLDV15M (B), and UbLDK48A
(C) upon ataxin-3 UIM123194-361 binding. Chemical shift perturbation maps of the
UbLD by measuring the absolute magnitude of peak shifting that occurs after addition of 6
eq.,5eq., and 4eq. of ataxin-3, respectively. The dotted lines indicate 0.5 S.D. above the
average chemical shift perturbation value. The surface representations of where the three
UIM containing region of ataxin-3 UIM123194-361 confer their binding spot on the wildtype
UbLD (A), UbLDV15M (B), and UbLDK48A (C). The residues that displayed more than 0.5
standard deviation above the average chemical shift were mapped on the surface of the UbLD,
which is highlighted in pink (wildtype UbLD), green (UbLDV15M) and orange (UbLDK48A).
The surface representations were created in the program PyMOL all using the PDB code
1IYF, structure of the wildtype human parkin UbLD.
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resonances that experienced some of the greatest chemical shift perturbations upon
titrations of ataxin-3 UIM123194-361 (Figures 3.3, 3.4). The interaction surface is similar
for ARJP substituted proteins UbLDV15M and UbLDK48A initially based on the
observations that multiple similar residues display chemical shift changes for both NMR
titration experiments. After further investigation, by using chemical shift perturbation
data and mapping the residues on the UbLD for chemical shift changes greater than 0.5
S.D. above the average chemical shift, it is clear that the surface of the beta-grasp fold is
utilized for ataxin-3 binding in both cases (Figure 3.5). The chemical shift perturbation
data show that upon substitution of a particular residue, the nearby residues that once
displayed a large absolute chemical shift difference upon addition of ataxin-3, greater
than 0.5 S.D. above the average chemical shift (dotted line), now display a much smaller
absolute change in chemical shift which is below the dotted line (Figure 3.5). An example
of this is the K48A substitution, because in the original wildtype interaction, residues
Lys48, Glu49, Ala46 all contribute to the binding surface for the UIM region of ataxin-3.
However, once Lys48 is substituted to an alanine, those nearby residues do not experience
a great chemical shift perturbation anymore (Figure 3.5C). The same occurs for the
UbLDV15M substitution. Nevertheless, even though these small differences occur, the
UbLDV15M and UbLDK48A utilize a similar binding surface to interact with ataxin-3
UIM123194-361 compared to each other and compared to the wildtype UbLD.
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3.3.4

Structurally unaffected ARJP-substituted UbLD proteins interact with ataxin-3

with a similar binding affinity
The data from the NMR titration experiments (Figure 3.3) was used to calculate
the affinities between the UbLD proteins, (UbLDK48A and UbLDV15M) and the ataxin-3
UIM123194-361. This analysis revealed that the affinities are very similar. Chemical shift
changes for five residues, Phe13, Val43, Leu61, Gln64 and Arg75, from the 1H-15N HSQC of
UbLDK48A spectra were plotted as a function of ataxin-3 UIM123194-361 additions (Figure
3.6). The resonances followed for the 1H-15N HSQC of UbLDV15M belonged to residues,
Phe13, Leu61, Gln64, Ser65, Val67, and also plotted as a function of ataxin-3 UIM123194-361
additions. The calculated dissociation constant for UbLDK48A was 658.9±48 µM and for
UbLDV15M was 700.4±102 µM. These dissociation constants were calculated based on a
global fit for a three-site multivalent binding model with equal binding affinities (Figure
3.6). These dissociation constants were very similar to that calculated for WT UbLD
binding to ataxin-3, Chapter 2. These observations show the ARJP substitutions do not
abolish the binding between the UbLD and ataxin-3.
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Figure 3.6 Binding curves of the absolute change in chemical shift of 15N
UbLDK48A and UbLDV15M with titrations of ataxin-3 UIM123194-361. The
absolute chemical shifts are taken into consideration, both the proton and
nitrogen chemical shifts (in ppm). The KD values are KD, UbLDK48A =
658.9±47.79 µM and KD, UbLDV15M = 700.4±102.7 µM and were based on a
global fit for a three equivalent multisite binding model. The starting
concentration of the ARJP substituted 15N UbLDK48A and UbLDV15M were 100
µM and 150 µM, respectively.
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3.4

Discussion
In this work the interactions between the ARJP substituted UbLD proteins and

three UIM regions of ataxin-3 were investigated mostly by the 1H-15N HSQC spectra
during titration experiments and the affinity-tag binding assays. Results show that the
structurally intact ARJP substitutions retain the interaction with the ataxin-3 UIMs. As
well, for the first time, dissociation constants were calculated for these interactions
between the UbLDV15M, UbLDK48A and ataxin-3194-361 and were found to have very
similar to the KD determined for the wildtype UbLD interaction. It should be noted that
the pathogenic link to ARJP UbLDK48A remains unclear although it has been reposted in
the literature (7). Protein characterization studies continue to study UbLDK48A, due to the
importance of the residue for interactions. Although this mutation has been reported, it
does

not

appear

in

Parkinson’s

disease

databases

(2,

7,

http://www.molgen.ua.ac.be/PDmutDB).

3.4.1

1

H-15N HSQC experiments show that UbLDV15M and UbLDK48A are structurally

intact
The dispersion of resonances in the proton dimension and the significant overlap
of resonances in the 1H-15N HSQC spectra between ARJP substituted UbLD proteins and
WT UbLD confirm that the protein domains remain well-folded with only local structural
changes. The UbLDK48A 1H-15N HSQC spectrum overlayed extremely well with that of
the WT UbLD spectrum, indicating no gross structural changes had occurred (Figure
3.1). Approximately half of the resonances that were different from the WT UbLD
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belonged to residues that were present in flexible regions, such as the C-terminal tail.
There were a greater number of differences in resonance positions between the
UbLDV15M 1H-15N HSQC spectrum compared to that of the WT UbLD, but this would be
expected due to the location of the Val15 position in the UbLD structure (Figure 3.1).
Unlike Lys48 position on the UbLD, which is solvent exposed, the Val15 position resides
on the β2 strand pointing towards the α2 helix. This suggests that the substitution of Val15
could modify intramolecular Van der Waals and hydrophobic interactions that stabilize
the fold of the protein such as that with Val29, which is located on the α2 helix and points
towards the Val15 side chain. The V15M substitution may be altering the existing
hydrophobic stabilizing interaction and this loss may change the chemical environment
for many residues that rely on this stabilization. Despite the greater number of resonances
that differ between the UbLDV15M 1H-15N HSQC spectrum and the UbLDWT spectrum
compared to the UbLDK48A 1H-15N HSQC spectrum and the UbLDWT, the conclusion is
that both UbLDV15M and UbLDK48A maintain the domain fold based on minimal changes
in the proton dispersion in the spectra and thus, exposes the essential interacting residues
in the hydrophobic patch to interact with the UIM region of ataxin-3.
In addition to the NMR experiments that were carried out, the structural integrity
of the V15M, R33Q, and K48A ARJP substitutions within the UbLD have been
previously studied by circular dichroism spectropolarimetry and NMR 1H-15N HSQC
experiments (2). The results are consistent with our findings by NMR spectroscopy.
These ARJP mutants maintain the five-strand β-grasp fold, typical of the UbLD and Ub
molecule, while A46P was completely unfolded (2). The 1H-15N HSQC spectra of
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UbLDV15M and UbLDK48A were identical to the spectra of previous work done to
characterize these two proteins (Figure 3.1) (2).

3.4.2

The affinity binding assay shows that the interaction between the structurally

unaffected disease-state UbLD proteins and UIMs of ataxin-3 are not disrupted
The affinity-binding assay was used as further confirmation and completeness of
determining if an ARJP substituted UbLD was able to disrupt the interaction to ataxin-3
UIM123194-361. The results showed that all proteins, WT UbLD, UbLDV15M, UbLDR33Q,
and UbLDK48A were able to interact with the UIM region of ataxin-3 and with similar
affinities (Figure 3.2). The UbLDA46P protein band appears more faint, suggesting that the
interaction with ataxin-3 is much weaker than the WT UbLD, UbLDV15M, UbLDR33Q, and
UbLDK48A (Figure 3.2). The ARJP substitution of a single amino acid, (V15M, K32T,
R33Q, and P37L) has been previously shown to compromise the interaction between the
UIM region of S5a (2). This led to the investigation of V15M, R33Q and K48A
substitutions, on the basis that they are all structurally intact and also because of their
close proximity to the binding interface of the UIM binding site on the UbLD. The
UbLDA46P has been shown previously to be completely unfolded, by the loss of alpha
helix and beta sheet signals in the CD spectra and by observing a collapse of peaks in the
NMR HSQC experiments, which is an indication of protein unfolding (2). Thus,
UbLDA46P was used as a negative control for the binding assay as the interaction surface
where UIMs typically bind would be disrupted and should result in no binding. However,
residual binding was detected for the UbLDA46P protein, possibly caused by nonspecific
binding to the resin of the column used (Figure 3.2). Analysis of the affinity binding
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assay alone provides a qualitative assessment that the structurally intact ARJP
substituted UbLD proteins are able to bind to ataxin-3 with a similar affinity compared
with UbLDWT.

3.4.3

NMR titration interaction studies between UbLDV15M, UbLDK48A and ataxin-3
The NMR titrations confirmed that the UbLDV15M and UbLDK48A utilize many

identical residues to interact with ataxin-3 UIM123194-361. The observation that Ile66,
Phe13, Leu61, and Gln64 participate in the interaction for both UbLDV15M and UbLDK48A
was expected, because these are also the residues that display great chemical shifts in the
NMR titrations of the wildtype interaction between the UbLD and UIMs as noted in
Chapter 2. Even though both residues Lys48 and Val15 participate in the wildtype
interaction, based on NMR titration experiments, the substitution of these residues does
not disrupt the binding significantly. The dissociation constant for UbLDK48A and
UbLDV15M were KD, UbLDK48A=658.9±47.79 µM and KD, UbLDV15M=700.4±102.7 µM for a
three equivalent multisite binding model (Figure 3.5). These KD values are not
significantly different from the wildtype KD which was 668.7±61.70 µM for a three
equivalent multisite binding model (Chapter 2). An explanation for why these two
particular structurally intact ARJP mutants did not drastically change the affinity of
binding to the UIM region could be because both residues do not lie at the centre of the
hydrophobic patch, which was found to be the ‘heart’ of the docking site for the ataxin-3
UIM region. Lys48 lies at the edge of the hydrophobic patch, on the β4 strand, while Val15
lies at the opposite edge of the hydrophobic patch with its side chain pointing away from
the solvent exposed beta sheet. The proximity of these two ARJP substitutions were not
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close to the center of the docking site for the UIMs and perhaps, are not important
residues for the interaction with the UIM region of ataxin-3. In support of this, previous
studies performed on ARJP substituted UbLD proteins and interactions with the UIM
region of S5a showed that the structurally intact ARJP-substituted proteins which
compromised the binding affinity to the S5a protein were residues that were interacting
with a key residue, Phe13, for the wildtype interaction between UbLD and UIM (2). Many
of the ARJP-substituted UbLD proteins also had decreased stability, based on thermal
unfolding experiments, which may have altered the interaction site for the S5a (2). Some
of the ARJP-substituted UbLD proteins that resulted in decreased domain stability were
also used in the study with ataxin-3, such as UbLDV15M and UbLDR33Q, however, the
decrease in stability does not effect the binding to ataxin-3. The structurally intact
disease-state UbLD substitutions that were studied for interactions with ataxin-3
(UbLDV15M, UbLDR33Q, and UbLDK48A), can all retain their interaction with ataxin-3.
This suggests that these particular ARJP substitutions may have a larger impact on
interactions to other proteins, such as S5a, or have an altered pathogenic pathway that
does not involve ataxin-3.

3.4.4

Alternate pathogenic pathways for ARJP-substituted UbLD proteins
Many identified ARJP substitutions within the UbLD of parkin have been

categorized in terms of how they could be contributing to pathogenic outcomes, such as
completely unfolding the UbLD structure, disrupting important protein-protein
interactions, or decreasing the stability of the domain structure and full-length parkin
protein (2, 8, 9). There are also unidentified pathogenic outcomes for some ARJP
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substitutions. Most recently, it has been proposed that the parkin UbLD has a role in
autoinhibition of its catalytic ubiquitin ligase activity, more specifically in
autoubiquitination (8). The N-terminal UbLD was found to interact with a ΔUbLD
parkin77-465 construct. The Lys48 position, which is completely conserved in ubiquitin and
acts as the site of polyubiquitin chain building for degradation signaling, had been shown
to be an essential residue to support the autoinhibited state of parkin (8). When the Lys48
was substituted with a non-charged residue alanine, as opposed to maintaining the same
charge with a residue like arginine, the autoinhibition was compromised and it resulted in
an increased autoubiquitination of parkin. This suggests that the electrostatic nature of the
Lys48 is essential to the intramolecular autoinhibited state of parkin, and that the
substitution of K48A could cause an increased turnover of parkin through the
proteasomal degradation pathway (8). Walden’s group also tested the UbLDA46P and
found that this ARJP substituted protein does disrupt the autoinhibition of parkin,
suggesting that the UbLD structure must be intact to be able to expose the residues most
important for interacting with a ΔUbLD parkin77-465 construct (8).
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Chapter 4
SUMMARY AND PERSPECTIVES

4.1

Introduction
The ubiquitin signaling pathway (USP) involves hundreds of enzymes and is

utilized in multiple regulatory pathways, such as proteasomal degradation, endocytosis
and DNA repair. Many protein misfolding neurodegenerative diseases have been linked
to the USP, which has drawn attention to the investigation of the structure and function of
enzymes involved in this multifaceted pathway. Conjugation of a Ub molecule or a polyUb chain onto a target protein is a tightly regulated process and it is also reversible. An
early-onset form of Parkinson’s disease (PD) has been linked with parkin, an E3 Ub
ligase, which participates in the last step of conjugating the Ub moiety onto a specific
target protein. Machado Joseph disease (MJD) is the most common dominantly inherited
ataxia and has been linked with a poly-glutamine expansion in the ataxin-3 DUB enzyme,
which has a role in detaching Ub moieties. Both MJD and PD are progressive diseases
and patients of these diseases can present with a wide variety of clinical symptoms.
Interestingly, the clinical presentations in MJD and PD can overlap, as it has been
reported that MJD patients have parkinsonism like behaviour (1).
4.2

Previous Work
There is potential for neuropathological overlap between the two disease states,

PD and MJD, since parkin and ataxin-3 are multi-domain proteins with an assemblage of
ubiquitin-signaling relevant domains. Observations of overlapping clinical symptoms for
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patients with Machado Joseph Disease (MJD) and patients with PD, such as tremors
and muscle rigidity, supports the hypothesis (1). In addition, similar areas of the brain are
negatively affected in MJD and PD, such as the substantia nigra; however, there are many
areas of the brain that are divergently affected in the two disease states (3). Some of the
patients with MJD that display parkinsonism characteristics, respond well to levodopa
treatment (4). These two proteins have already been identified to be functionally
interactive by their interplay between ubiquitylating and deubiquitinating one another to
regulate the function of both proteins (2,5). All of the clinical observations and
experimental evidence emphasizes the importance of the interaction between parkin and
ataxin-3. Further investigation needs to be focused on how the disease-relevant
mutations, on either parkin or ataxin-3, affect the neurobiology in affected areas in the
brain.
In 2010, parkin was reported to directly interact with ataxin-3, however details
regarding the residues involved in the binding site, binding mechanism and affinity of
binding were not elucidated (2). By performing multiple affinity binding assays, the
group was able to narrow down the binding region to the C-terminal UIM region of
ataxin-3 and the N-terminal UbLD of parkin (2). In Dr. Fon’s group, they found that
GST-tagged parkin lacking the UbLD could still bind to full-length ataxin-3, which
suggests that there is another interaction site. Further investigation led to the discovery
that is was an interaction between the ataxin-3 N-terminal Josephin domain with the IBRRING2 of parkin (2). In this work, the focus was only on the UbLD and UIM constructs,
but if this interaction is complicated by another site of binding, further investigation is
needed to fully appreciate the biological binding mechanism between ataxin-3 and
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parkin. It would be interesting to determine the binding affinity of this interaction
through NMR titration experiments, however, the Josephin domain and IBR-RING2
would form a much larger complex than the UIM region and UbLD. The large complex
will slow the tumbling time in the protein sample and the peaks may be difficult to
resolve due to the broadening of peaks. It is important to study the second potential
interaction site because it could be the site of disease pathogenesis for either ARJP or
MJD.

4.3

Interactions between the parkin UbLD and UIM region of ataxin-3
Thorough analysis of eight different sets of NMR titration experiments, using

multiple ataxin-3 UIM region constructs of various lengths and sequences and the parkin
UbLD, were carried out to provide the first reports of the site (on parkin) for the
interaction, strength of the interaction and proposal of a mechanism of binding between
parkin and ataxin-3. The UIM region of ataxin-3, spanning residues 194-361 (including
all three UIM sites), were found to bind to the beta-grasp fold on the UbLD of parkin.
This binding region on the UbLD is called the hydrophobic patch, which includes
residues Ala46, Ile66, and Val67 as well as a few basic residues, such as Lys48. The betagrasp surface on the parkin UbLD is also the binding site for two other UIM-containing
proteins, S5a and Eps15, though there are variations in the size of the binding surface
because of the difference in how many UIM sites are utilized in the interaction (8). The
binding surface area where the UIM region of ataxin-3 binds to the UbLD, in comparison
to previous studies, can be predicted to bind one to two UIM sites but is not large enough
to simultaneously interact with all three UIM sites. Interestingly, the NMR titrations
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involving C-terminal deletions of the ataxin-3 UIM region suggested that when all
three UIM sites are intact, the binding affinity is the tightest. The evidence for this was
displayed by determining the KDs by fitting the binding curves to the macroscopic or
simple 1:1 binding model; the KDs were 230 µM, 430 µM, and >2 mM for ataxin-3
regions 194-361 (3 UIM sites), 194-261 (2 UIM sites), and 194-244 (1 UIM),
respectively. This led to the proposal that a multivalent binding mechanism could be
utilized by all three UIM binding regions of ataxin-3 upon interacting with parkin.
Multivalent binding involves rapid kinetic substrate binding, of typically a tandem string
of binding moieties; in this case the ataxin-3 UIM sites were proposed to be
interchanging amongst one another in an intramolecular fashion at a rapid rate.
Interestingly, this type of multivalent binding mechanism has been characterized for
another UIM-containing protein involved in DNA repair, called Rap80, and its
interaction with poly-ubiquitin chains (9).

4.4

ARJP substitutions on the UbLD and the effect on its interaction with ataxin-

3
Three structurally unaffected ARJP substituted UbLD proteins, chosen based on
residue positions that were within or proximal to the binding surface for ataxin-3, were
analyzed for their effect on the interaction with ataxin-3 UIM123194-361. Out of 20
possible ARJP substitutions within the parkin UbLD, the ones that were the focus of this
study were UbLDV15M, UbLDR33Q, and UbLDK48A (5). All three ARJP substituted proteins
were able to retain their interaction with the UIM region of ataxin-3, based on an affinitytag binding assay. A detailed analysis was carried out for UbLDV15M and UbLDK48A, by
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H-15N HSQC titration experiments, for determination of the binding site on the UbLD

and the binding affinity. Results showed that although the binding site was not identical
for ataxin-3 binding to UbLDV15M and UbLDK48A, there were many identical residues that
shifted upon additions of ataxin-3. The binding site on the UbLDK48A and UbLDV15M,
where the UIM region of ataxin-3 binds, was found to be on the solvent exposed surface
of the beta-grasp fold, which is where the wildtype binding site is located. The KD values
for the interaction between the UbLDV15M and UbLDK48A to ataxin-3194-361 were similar to
that of the wildtype UbLD interaction, all of them within the 650-750 µM range for a
multivalent binding fit. Therefore, the ARJP-substituted UbLD proteins used in this study
are all able to interact with ataxin-3 UIM123194-361, and likely uses a similar mechanism
to recruit ataxin-3 UIM123194-361.

4.5

Conclusions
The work presented here has contributed to the understanding of how an E3

ubiquitin ligase, parkin, recognizes a DUB enzyme, ataxin-3. Parkin was previously
reported to directly interact with ataxin-3 by affinity binding assays but details regarding
the binding affinity, recognition surface and mechanism of binding were not
characterized until now (2). This work provides the first detailed understanding of where
and

how

the

three

UIM

regions

in

ataxin-3 make

a

weak

interaction

(KD,macroscopic=230µM) with the parkin UbLD, and is proposed to use a multivalent
binding mechanism to do so. Choosing only the structurally unaffected ARJP substituted
UbLD proteins, based on previous structural characterization, provides the first analysis
of the disease state UbLD proteins and their effect on the binding affinity and UbLD
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binding surface upon addition of ataxin-3. These analyses showed that the interaction
between the UbLDV15M, UbLDR33Q, UbLDK48A and ataxin-3 is retained and that the
V15M and K48A substitutions do not completely alter the site of interaction on the
UbLD.
The interaction between these two proteins is very interesting because they
possess opposing functions of either attaching or detaching a Ub moiety from specific
substrates or one another (2). The interactions between other DUB enzymes and E3
ligases have been reported, which has triggered interest in studying the biological
importance and interplay between these protein pairings (2, 6). There is also evidence to
suggest that there is regulatory interplay for the catalytic activity of parkin and ataxin-3,
which provides another piece of evidence to explain why their interaction is biologically
important (2, 4, 7). The USP is a complex system consisting of hundreds of enzymes and
even more target proteins, which all need to be orchestrated for proper maintenance of
intracellular protein level homeostasis. Due to the complexity of the USP, there are still
many protein networks that need to be understood in order to address the
neurodegenerative USP-linked disease states, such as ARJP and MJD.
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